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ABSTRACT 
 
ROLE OF PIKFYVE IN PLATELET LYSOSOMAL HOMEOSTASIS 
Sang Hee Min 
Charles S. Abrams 
 
PIKfyve is a lipid kinase that is essential for the synthesis of phosphatidylinositol-3,5-
bisphosphate [PtdIns(3,5)P2], and for the regulation of membrane dynamics within the 
endolysosomal system in mammals. Depletion of intracellular pools of PtdIns(3,5)P2 in 
humans and in mice is associated with neurodegeneration and early lethality. However, 
the biological role of PtdIns(3,5)P2 in non-neural tissues is not well understood. Platelets 
are hematopoietic cells that function in a variety of physiological responses. Essential to 
many of these functions is the activation-dependent release of effectors from distinct 
storage granules - alpha granules, dense granules, and lysosomes - that derive from the 
endolysosomal system. In this work, we show that platelet-specific ablation of the 
PIKfyve gene in mice results in accelerated arterial thrombosis, but also unexpectedly to 
multiorgan defects that impair development, body mass, fertility, and survival by 
inducing inappropriate inflammatory responses characterized by macrophage 
accumulation in multiple tissues. Platelet depletion in vivo significantly impairs the 
progression of multiorgan defects in these mice, confirming that these defects reflect a 
platelet-specific process. Although PIKfyve-null platelets generate and release normal 
amounts of alpha granule and dense granule contents, they develop defective maturation 
and excessive storage of lysosomal enzymes, which are released upon platelet activation. 
Remarkably, impairing the secretion of lysosomes from PIKfyve-deficient platelets in 
vivo significantly attenuates the multiorgan defects in mice, suggesting that platelet 
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lysosome secretion contributes to pathogenesis. Together, these results demonstrate that 
PIKfyve is an essential regulator for the biogenesis of platelet lysosomes, and highlight 
the previously unrecognized and important pathological contributions of platelet 
lysosomes in inflammation, arterial thrombosis, and macrophage biology. 
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CHAPTER 1: INTRODUCTION 1 
 
1.1) Phosphoinositides: overview  
Phosphatidilinositol (PtdIns) is a class of membrane phospholipid, which is 
composed of an inositol head group, a glycerol backbone, and two fatty acid tails. PtdIns 
is modified by transient phosphorylation of its inositol head group, which generates 
various phosphorylated forms of PtdIns, known as phosphoinositides (Hokin and Hokin 
1953, Hokin 1996). PtdIns and phosphoinositides are very minor components of the 
membrane phospholipids, and yet they are essential in the regulation of diverse cellular 
processes, which include membrane trafficking, cytoskeletal dynamics, membrane 
transports, and nuclear events in many different cells (Di Paolo and De Camilli 2006).  
A total of seven phosphoinositides have been identified that derive from PtdIns 
following the reversible phosphorylation of the hydroxyls situated in the D3, D4 and D5 
positions of the inositol head group. These seven phosphoinositides are: PtdIns(3)P, 
PtdIns(4)P, PtdIns(5)P, PtdIns(3,5)P2, PtdIns(3,4)P2, PtdIns(4,5)P2, and PtdIns(3,4,5)P3 
(Figure 1). The turnover of phosphoinositides occurs on the cytosolic leaflet in the 
cellular membrane or on the membrane of intracellular organelles by specific 
phosphoinositide-metabolizing enzymes, which include lipid kinases, lipid phosphatases, 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  Parts of this chapter have been published as: 
Min SH, Abrams CS 
Regulation of platelet plug formation by phosphoinositide metabolism. 
Blood. 2013 Aug 22;122(8):1358-65. 
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and phospholipases (Heck, Mellman et al. 2007, Krauss and Haucke 2007). The 
individual phosphoinositide-metabolizing enzymes have distinct expression and 
regulation patterns and contribute to the spatiotemporal organization of specific 
phosphoinositides (Krauss and Haucke 2007). Consequently, the different 
phosphoinositides are rapidly and reversibly generated on the membranes of distinct 
cellular compartments.  
 
 
Figure 1.1. Metabolism of phosphoinositides by phosphoinositide-metabolizing 
enzymes. Shown is the relationship between different phosphoinositides and their 
metabolizing lipid kinases (red arrows), lipid phosphatases (blue arrows) and 
phospholipase C (green arrows).  
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Once synthesized, the individual phosphoinositides can be recognized by selective 
subsets of proteins containing specific phosphoinositide-binding domains, such as PH 
(pleckstrin homology), FYVE (Fab1, YOTB, Vac1, EEA1 homology), PX (phox 
homology), PROPPINs (β-propellers that bind phosphoinositides), ENTH (epsin N-
terminal homology), and ANTH (AP180 N-terminal homology) (Lemmon 2008). For 
example, PtdIns(4,5)P2 on the plasma membrane binds to ENTH domain of Epsin and 
indirectly recruit Epsin binding proteins such as AP2 to bind clathrin coats and form 
clathrin-coated vesicles. This recruitment of a specific effector protein to a 
phosphoinositide confined in a specific cellular compartment provides each of the 
individual phosphoinositides with unique functions in cells.  
The essential physiological functions of phosphoinositides have been 
demonstrated by many human disorders or abnormal phenotypes in mice associated with 
mutations in the phosphoinositide-metabolizing enzymes (Nicot and Laporte 2008, 
McCrea and De Camilli 2009).   
 
1.2) Phosphoinositide organization during platelet plug formation 
Platelet plug formation is essential during hemostasis, but when perturbed, it can 
lead to pathological bleeding or thrombosis (Jackson 2011). Thus, this is a tightly 
controlled process requiring activation of platelets under carefully modulated intracellular 
signaling transduction (Jackson 2007, Stalker, Newman et al. 2012). When there is a 
vascular injury, platelets tether to collagen or to von Willebrand factor (vWF) and initiate 
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an intracellular signaling cascade that leads to firm and stable adhesion to the 
subendothelium (Ruggeri and Mendolicchio 2007). This is followed by integrin 
activation on the platelet surface, and subsequently aggregation between platelets 
(Jackson 2007).  Further stabilization of the platelet plug and prevention of platelet 
disaggregation requires additional amplification of the platelet signaling pathways. Over 
the past few decades, accumulating evidence indicates that phosphorylated 
phosphatidylinositols are crucial components in this complex network of platelet 
signaling.  
 
The role of PtdIns(4,5)P2 signaling in platelet biology 
PtdIns(4,5)P2 synthesis by PIP5KI 
PtdIns(4,5)P2 is a predominant phosphoinositide in the cellular membrane.  
PtdIns(4,5)P2 is synthesized either from PtdIns(4)P by the D5-OH kinase activity of 
PIP5KI (Hay, Fisette et al. 1995) or from PtdIns(5)P by the D4-OH kinase activity of 
phosphatidylinositol 5-phosphate 4-kinase type II  (PIP5KII or PIP4K) (Rameh, Tolias et 
al. 1997, Clarke, Wang et al. 2010). Studies comparing the relative labeling rate of the 
D4- and D5- hydroxyl positions of the inositol ring suggest that the catalytic activity of 
the D5 position is more efficient (King, Hawkins et al. 1989, Stephens, Hughes et al. 
1991). In addition, the relative abundance of PtdIns(4)P is much greater than PtdIns(5)P 
(Stephens, Hughes et al. 1991, Roberts, Clarke et al. 2005), suggesting that PIP5KI 
phosphorylation of PtdIns(4)P is the major source of PtdIns(4,5)P2 synthesis. In 
agreement with these findings, while the loss of PIP4K does not reduce the synthesis of 
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PtdIns(4,5)P2 in mammalian cells, the loss of PIP5KI significantly decreases the 
intracellular pool of PtdIns(4,5)P2. This demonstrates that PIP5KI is the predominant 
kinase in the generation of PtdIns(4,5)P2.  
 
PIP5KI isoforms and splice variants in platelets 
PIP5KI exists in three different isoforms (α, β and γ). Intriguingly, all three 
PIP5KI isoforms can synthesize PtdIns(4,5)P2 from PtdIns(4)P (Ishihara, Shibasaki et al. 
1996, Loijens and Anderson 1996, Ishihara, Shibasaki et al. 1998).  This in turn raises the 
question why PIP5KI exists in more than one isoform? Recently, work by our group as 
well as by others addressed this question using genetically engineered mice lacking each 
isoform of PIP5KI in platelets. Platelets contain all three isoforms of PIP5KI, but the 
murine PIP5KI-β and PIP5KI-γ are the most abundant forms (Wang, Chen et al. 2008, 
Wang, Litvinov et al. 2008). Platelets lacking PIP5KI-β have defective synthesis of 
PtdIns(4,5)P2 as well as defective Ins(1,4,5)P3 formation in the first one minute after 
stimulation with thrombin (Wang, Chen et al. 2008). Consequently, these platelets 
display defective aggregation ex vivo and impaired formation of an occluding thrombus 
in vivo (Wang, Chen et al. 2008). Remarkably, platelets lacking both PIP5KI-α and 
PIP5KI-β have a complete loss of Ins(1,4,5)P3 formation, even though they still contain 
PIP5KI-γ (Wang, Chen et al. 2008). This suggests that PIP5KI-γ synthesizes a pool of 
PtdIns(4,5)P2 that is not required for the synthesis of second messengers such as 
Ins(1,4,5)P3.  
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As predicted, platelets lacking PIP5KI-γ can still produce normal amounts of 
Ins(1,4,5)P3 upon stimulation with thrombin, despite having impaired synthesis of 
PtdIns(4,5)P2 (Wang, Litvinov et al. 2008). But in contrast to cells lacking PIP5KI-α or 
PIP5KI-β, megakaryocytes or platelets lacking PIP5KI-γ have a significant defect in 
anchoring their cell membranes to the underlying cytoskeleton (Wang, Litvinov et al. 
2008, Wang, Zhao et al. 2013). This suggests that PIP5KI-γ synthesis of PtdIns(4,5)P2 
does not contribute to Ins(1,4,5)P3 formation, but rather directly affects the membrane 
anchoring of the cytoskeleton. Additional evidence suggests that PIP5KI-γ synthesizes a 
discrete pool of PtdIns(4,5)P2 that interacts directly with actin-binding proteins (such as 
talin) (Di Paolo, Pellegrini et al. 2002, Ling, Doughman et al. 2002). Once bound to 
PtdIns(4,5)P2, these actin-regulating proteins are enabled to anchor the cell membrane to 
the underlying cytoskeleton (Gilmore and Burridge 1996).  
These studies demonstrate that although all PIP5KI isoforms can synthesize 
PtdIns(4,5)P2, they have non-redundant functional roles in platelets. How the different 
isoforms of PIP5KI promote unique physiological effects is unclear, but several 
mechanisms are proposed. First, although PIP5KI-α and PIP5KI-β have homologous 
primary sequences, PIP5KI-γ is structurally different (Loijens and Anderson 1996, Wang, 
Chen et al. 2008). This suggests that individual PIP5KI isoforms could be regulated 
differently. Second, spatially distinct localization of individual PIP5KI isoforms may 
generate discrete pools of PtdIns(4,5)P2. Several studies indicate that different PIP5KI 
isoforms are localized in distinct cellular compartments in tissue culture cells. For 
instance, PIP5KI-α is more predominant in membrane ruffles (Doughman, Firestone et al. 
2003), while PIP5KI-β concentrates close to the endosomes (Padron, Wang et al. 2003), 
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and PIP5KI-γ is targeted to focal adhesions and nerve terminals (Wenk, Pellegrini et al. 
2001, Di Paolo, Pellegrini et al. 2002, Ling, Doughman et al. 2002). In addition, our data 
indicate that PIP5KI-α and PIP5KI-β, but not PIP5KI-γ can synthesize the pool of 
PtdIns(4,5)P2 utilized by PLC to generate Ins(1,4,5)P3 (Wang, Chen et al. 2008, Wang, 
Litvinov et al. 2008). From these studies, one could hypothesize that the pools of 
PtdIns(4,5)P2 from different PIP5KI isoforms are highly compartmentalized and targeted 
by selective downstream effector molecules, providing unique functions to each of the 
PIP5KI isoforms. However, it is also conceivable that only PIP5KI-α and PIP5KI-β can 
interact with auxiliary proteins that in turn regulate the activity of downstream effectors 
such as PLC. Nevertheless, the exact mechanisms by which different PIP5KI isoforms 
fulfill unique niches within platelets need to be further elucidated.  
As mentioned above, several groups of researchers have speculated that PIP5KI-γ 
might generate PtdIns(4,5)P2 that binds to talin and positions it to participate in signaling 
pathways that emanate towards or in response to integrin activation (Gilmore and 
Burridge 1996, Di Paolo, Pellegrini et al. 2002, Ling, Doughman et al. 2002, Calderwood 
and Ginsberg 2003). PIP5KI-γ has two predominant splice variants that differ by the 
inclusion of or exclusion of 27 amino acids encoded by the terminal exon of the PIP5K-γ 
gene (Di Paolo, Pellegrini et al. 2002, Ling, Doughman et al. 2002). These two splice 
variants are the longer 90 kDA (p90) splice form and the shorter 87 kDa (p87) splice 
form.  These additional 27 amino acids allow the p90 splice variant to bind to talin, a 
protein that is important for both integrin activation and for linking integrins to the 
underlying cytoskeleton (Di Paolo, Pellegrini et al. 2002, Ling, Doughman et al. 2002, 
Calderwood and Ginsberg 2003). Consequently, platelets and megakaryocytes lacking 
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the p90 splice variant of PIP5KI-γ have defective anchoring of their integrins to the 
underlying cytoskeleton (Wang, Zhao et al. 2013). This effect depends on the kinase 
activity of PIP5KI-γ, which implies that the local synthesis of PtdIns(4,5)P2 by the p90 
splice variant plays an important role in maintaining the integrity of the connection 
between the cell membrane and actin. Remarkably, platelets lacking this p90 splice 
variant of PIP5KI-γ have no obvious defect in the activation of integrins or in cell 
adhesion. In contrast, platelets lacking both p87 and p90 PIP5KI-γ do have a defect in 
shear-resistant adhesion (Wang, Zhao et al. 2013). These data suggest that although both 
the p87 and p90 PIP5KI splice variants can synthesize PtdIns(4,5)P2, they have non-
redundant functions in platelet cytoskeletal dynamics and in stable adhesion. This study 
further provides evidence that PIP5KI has a variety of intracellular functions. Not only 
does PIP5KI produce isolated pools of PtdIns(4,5)P2, it also, because of its individual 
isoforms and splice variants, can directly interact and regulate distinct signaling proteins.  
 
Regulation of PIP5KI by small GTPases 
Several studies suggest that the localization and kinase activity of PIP5KI 
isoforms are regulated by small GTPases of the Rho family. For instance, J. Hartwig and 
colleagues demonstrated that thrombin-mediated Rac1 activation induces the synthesis of 
PtdIns(4,5)P2 by PIP5KI-α, which in turn leads to actin filament assembly (Hartwig, 
Bokoch et al. 1995). The S. Offermanns group showed that exposure of platelets to 
thromboxane A2 stimulates Rho and Rho kinase, which thereby activate PIP5KI 
(Gratacap, Payrastre et al. 2001). We have shown that PIP5KI is rapidly translocated 
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from the cytosol to actin-rich compartments upon platelet activation, but this process is 
impaired when the Rho GTPase is inhibited (Chatah and Abrams 2001, Yang, Carpenter 
et al. 2004). Together, these works suggest that Rho family GTPases regulate the 
trafficking of PIP5KI into the membrane cytoskeleton.  Once PIP5KI is positioned next 
to its substrate, PtdIns(4)P, PIP5KI is poised to generate PtdIns(4,5)P2.  
 
The role of second messengers Ins(1,4,5)P3 and DAG in platelet biology  
Phospholipase C (PLC) hydrolyzes PtdIns(4,5)P2, thereby cleaving the bond 
between the glycerol and phosphate moieties to generate the second messengers DAG 
and IP3 (Figures 3A) (Eyster 2007). PLCs are classified into six subfamilies based on 
sequence homology.  They are: PLC-β, PLC-γ, PLC-δ, PLC-ε, PLC-ζ and PLC-η. Many 
of these PLC isoforms have multiple variants, leading to a very large and diverse family 
of enzymes (Rhee and Choi 1992). Although all PLC isoforms can hydrolyze 
PtdIns(4,5)P2 to generate DAG and Ins(1,4,5)P3, each PLC isoform has distinct cellular 
expressions, subcellular localizations, and specific modes of activation (Rhee and Bae 
1997). This diversity further contributes to the temporo-spatial metabolism of 
PtdIns(4,5)P2 signaling.   
Ins(1,4,5)P3  is a soluble second messenger that can diffuse through the cytosol 
and bind to Ins(1,4,5)P3 receptors (Berridge and Irvine 1989), which in turn function as 
Ca2+ channels in the platelet dense tubular systems (DTS). This triggers Ca2+ release from 
the DTS to the cytosol, which in turn modifies the cytosolic concentrations of Ca2+, and 
regulates diverse downstream signaling effects that include the release of platelet 
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secretory granules (Brass and Joseph 1985). In contrast to Ins(1,4,5)P3 generated by 
PLC-mediated hydrolysis of PtdIns(4,5)P2, the second messenger DAG simultaneously 
generated by this process functions as a signaling molecule that is essential for the 
localization and activation of different isoforms of protein kinase C (PKC) (Lapetina, 
Reep et al. 1985). In turn, PKC has regulatory functions in many cellular processes, 
which include proliferation, apoptosis, survival, and migration (Lapetina, Reep et al. 
1985, Griner and Kazanietz 2007). In platelets, DAG-mediated activation of PKC also 
leads to the phosphorylation of a 47kDa protein called pleckstrin, which is a protein that 
is important in platelet secretion (Lian, Wang et al. 2009).  
Human platelets contain PLC-β and PLC-γ. PLC-β has a pleckstrin homology 
(PH) domain that binds to the Gβγ subunit of the heterotrimeric G protein on the plasma 
membrane. This process activates the catalytic domains of PLC-β.  Conversely, after 
collagen stimulation, PLC-γ binds to the PtdIns(3,4,5)P3 on the plasma membrane, where 
it can be directly phosphorylated by receptor tyrosine kinases (RTK). Upon platelet 
activation, all PLC isoforms induce the rapid hydrolysis of PtdIns(4,5)P2 into DAG and 
Ins(1,4,5)P3. Patients who have a deficiency of PLC-β, have a mild bleeding disorder 
(Lee, Rao et al. 1996, Yang, Sun et al. 1996).  Ex vivo, platelets from these patients, or 
mice engineered to lack PLC-β isoforms, exhibit abnormal platelet aggregation and 
secretion (Lian, Wang et al. 2005).  This is due to diminished PLC-β–mediated 
Ins(1,4,5)P3 production, intracellular Ca2+ mobilization, and pleckstrin phosphorylation 
(Lee, Rao et al. 1996, Yang, Sun et al. 1996, Lian, Wang et al. 2005).  
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The role of PtdIns(3,4,5)P3 signaling in platelet functions  
PI3K isoforms  
Phosphatidylinositol 3-kinases (PI3Ks) can phosphorylate the D3-OH group of 
the inositol ring within phosphoinositides to generate PtdIns(3,4,5)P3, PtdIns(3,4)P2, and 
PtdIns(3)P (Cantley 2002). There exist three classes of PI3K isoforms (I, II and III) 
(Vanhaesebroeck and Waterfield 1999). The class I PI3K are critical for the 
phosphorylation of PtdIns(4,5)P2 to generate the second messenger PtdIns(3,4,5)P3 (also 
known as PIP3) (Anderson and Jackson 2003). This class of PI3K is subdivided into class 
IA (PI3K-α, PI3K-β and PI3K-δ) and IB (PI3K-γ). The class IA PI3K is a heterodimer 
that is composed of a catalytic subunit (p110-α, p110-β, and p110-δ) bound to a 
regulatory subunit (p85-α, p85-β, p55-γ, p55-α and p50-α) that possesses an SH2 (Src 
homology 2) motif. Since SH2 domains bind to tyrosine phosphorylated residues on other 
proteins, the regulatory subunit enables class IA PI3K to bind to tyrosine phosphorylated 
receptor tyrosine kinases or to adaptor molecules (Gibbins, Briddon et al. 1998). This 
process unfolds the PI3K complex, and enables it to phosphorylate PtdIns(4,5)P2 to 
generate PtdIns(3,4,5)P3. In contrast, the single member of the class IB PI3K family 
(PI3K-γ) is composed of the catalytic subunit p110-γ and the p101 regulatory domain. 
This complex becomes enabled to synthesize PtdIns(3,4,5)P3 after p101 binds to the Gβγ 
subunit of heterotrimeric G-proteins. However, recent studies suggest that PI3K-β can 
also be activated by G protein coupled receptors (GPCRs) (Tang and Downes 1997, 
Hazeki, Okada et al. 1998, Kubo, Hazeki et al. 2005) (Guillermet-Guibert, Bjorklof et al. 
2008). Regardless of the mechanism, activation of all Type I PI3Ks lead to the synthesis 
of PtdIns(3,4,5)P3, which in turn can bind to and activate many downstream effector 
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molecules, including the protein kinase, Akt. In addition to class I PI3K isoforms that 
synthesize PtdIns(3,4,5)P3, there are class II PI3Ks that phosphorylate PtdIns(4)P to 
synthesize PtdIns(3,4)P2, and there are class III PI3Ks that phosphorylate the D-3 
position of PtdIns to form PtdIns(3)P. While the role of class I PI3K in platelet adhesion 
by activation of αIIbβ3 has been extensively studied (Jackson, Yap et al. 2004, Gratacap, 
Guillermet-Guibert et al. 2011), the function of class II and class III PI3Ks in platelets is 
not well established. 
 
The role of class I PI3K isoforms in platelet plug formation 
Human and mouse platelets contain all isoforms of class I PI3K including α, β, 
and γ, and even small amounts of PI3K-δ (Vanhaesebroeck, Welham et al. 1997, Zhang, 
Vanhaesebroeck et al. 2002, Watanabe, Nakajima et al. 2003, Jackson, Yap et al. 2004). 
The binding of collagen to the platelet GPVI receptor leads to the phosphorylation of the 
receptor’s FcRγ chain, which allows it to bind to the SH2 domain of PI3K-α, PI3K-β and 
PI3K-δ (Falet, Barkalow et al. 2000, Watanabe, Nakajima et al. 2003). Conversely, 
activation of the P2Y12 receptor leads to the release of the Gβγ subunit from 
heterotrimeric G-proteins that binds the p101 subunit of PI3K-γ and activates this lipid 
kinase complex (Heraud, Racaud-Sultan et al. 1998, Trumel, Payrastre et al. 1999) 
(Kauffenstein, Bergmeier et al. 2001). Activation of all type I PI3Ks lead to the synthesis 
of PtdIns(3,4,5)P3, which in turn activate the protein kinase, Akt (Chen, De et al. 2004, 
Woulfe, Jiang et al. 2004) in platelets. In addition, PtdIns(3,4,5)P3 also facilitates the 
activation of PLC-γ (Gilio, Munnix et al. 2009). Together, these signaling events have 
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been shown to contribute to the activation of the small GTPase Rap1b, which is an 
activator of integrin αIIbβ3 (Canobbio, Stefanini et al. 2009).  
Initial studies using PI3K inhibitors that block all isoforms of PI3K such as 
wortmannin and LY294002 suggested that PI3K is crucial for platelet adhesion and 
aggregation under high shear (Yap, Anderson et al. 2002, Kasirer-Friede, Cozzi et al. 
2004). However, the exact contribution of individual isoforms of PI3K during platelet 
activation remained largely unknown. Over the past few years, studies using isoform-
specific targeted mouse models and PI3K inhibitors provided strong evidence that the 
different isoforms of class I PI3K have distinct cellular and physiological functions in 
diverse cell types including in platelets. For instance, it is now established that PI3K-α is 
crucial for cell growth and survival. This has implications in oncogenesis, and targeting 
of PI3K-α is being investigated as a strategy for chemotherapeutics (Stephens, Williams 
et al. 2005). Conversely, PI3K-γ plays an essential role in innate immunity and 
inflammatory responses (Camps, Ruckle et al. 2005, Ruckle, Schwarz et al. 2006) while 
PI3K-δ is crucial for adaptive immunity involving B and T cells and mast cells 
(Okkenhaug and Vanhaesebroeck 2003, Ali, Bilancio et al. 2004). In platelets, PI3K-δ 
knockout mice and kinase-deficient PI3K-δ knockin mice have only a minor defect in the 
GPVI-mediated activation of integrin αIIbβ3(Senis, Atkinson et al. 2005). This implies 
that other PI3K isoforms are the major mediators of collagen-induced platelet adhesion 
and aggregation. Remarkably, in vivo inhibition of PI3K-β impairs the formation of 
stable αIIbβ3-mediated platelet adhesion and prevents thrombus formation in mice, even 
though it does not increase the bleeding time (Vanhaesebroeck, Ali et al. 2005). This 
finding suggests that drugs that inhibit PI3K-β might not cause significant hemorrhage 
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when given to patients for brief periods of time, such as during cardiac catheterization 
(Jackson and Schoenwaelder 2006). Similarly, mice lacking PI3K-γ have defective 
platelet aggregation upon stimulation with the platelet agonist ADP. Moreover, these 
mice are less prone to form thrombi in response to intravenous injections with ADP. It 
should be noted that these mice do not have spontaneous bleeding, again suggesting that 
PI3K-γ might be a viable target for inhibiting thrombosis formation without inducing 
excessive hemorrhage (Hirsch, Bosco et al. 2001, Lian, Wang et al. 2005). Additional 
studies support that the functional role of PI3K-β and PI3K-γ in platelets are both 
required for ADP- or thromboxane A2- induced activation of the Rap1b (Canobbio, 
Stefanini et al. 2009). However, only PI3K-β (and not PI3K-γ) was necessary for 
collagen-stimulated signaling pathways that lead to Akt phosphorylation, Rap1b 
activation, and platelet aggregation (Canobbio, Stefanini et al. 2009). Together, these 
studies suggest a story that is similar to what is seen in PIP5KI isoforms. Even though all 
PI3K class I isoforms can produce PtdIns(3,4,5)P3, the individual isoforms have non-
redundant roles in platelets.  
 
1.3) PtdIns(3,5)P2 and trafficking to the lysosome  
Trafficking to the lysosome 
Lysosomes are organelles essential for intracellular degradation and recycling. 
However, recent studies indicate that lysosomes also play a critical role in cellular 
metabolism, signaling, repair and secretion (Settembre, Fraldi et al. 2013). To carry out 
these functions, lysosomes receive substrates from endocytosis, phagocytosis and 
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autophagy. In addition, newly synthesized soluble and membrane-bound lysosomal 
proteins are delivered from the TGN (trans-golgi network) to the lysosome (Saftig and 
Klumperman 2009).  
Endocytosis involves the internalization of substrates from the plasma and its 
delivery to the lysosome passing through a series of endosomal intermediates (Luzio, 
Parkinson et al. 2009). In this dynamic process, membranes and proteins are constantly 
outgoing and incoming to undergo a gradual remodeling process called maturation 
(Huotari and Helenius 2011). The different endosomal intermediates resulting from this 
maturation process include early endosomes, and multivesicular bodies/late endosomes. 
In multivesicular bodies, the internalized cargo destined for degradation is sorted into 
intraluminal vesicles (Luzio, Piper et al. 2009). The more mature forms of multivesicular 
bodies are called late endosomes. These endosomal intermediates can be distinguished by 
their content, molecular make-up, morphology, pH and kinetics of endocytic tracers 
(Saftig and Klumperman 2009). Subsequently, the limiting membranes of late endosomes 
fuse with lysosomes to form an intermediate structure called hybrid organelles. This 
process is called endosome-lysosome fusion (Luzio, Pryor et al. 2007). This fusion 
process requires well-coordinated activities of different protein complexes involved in the 
biogenesis of late endosomes, endosome-lysosome tethering and endosome-lysosome 
fusion. These protein complexes include the ESCRT (endosomal sortin complex required 
for transport), HOPS (homotypic fusion and vacuole protein sorting) and trans-SNARE 
(soluble N-ethylmaleimide-sensitive factor-attachment protein receptor) complexes 
(Luzio, Gray et al. 2010). The resulting hybrid organelles display markers of endosomes 
and lysosomes. Eventually, the lysosome is recycled from the hybrid organelle by a 
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maturation process that includes condensation of content, removal of non-lysosomal 
membrane proteins and recycling of SNAREs (Luzio, Pryor et al. 2007).  
Lysosomes can receive substrates from the extracellular or intracellular sources. 
During endocytosis, extracellular substrates are internalized and their luminal contents 
are delivered to the lysosome for degradation. During autophagy, the intracellular 
organelles are internalized to form autophagosomes, which fuse with lysosomes to form 
autolysosomes for the degradation of their luminal contents.  To carry out these 
degradative functions, it is essential that lysosomes receive the necessary soluble 
hydrolytic enzymes and membrane-bound lysosomal proteins delivered through the 
biosynthetic pathway. 
The delivery of newly synthesized proteins from the TGN to the lysosome can be 
direct or indirect (Saftig and Klumperman 2009). The direct pathway is used by many of 
the hydrolases. They are synthesized in the ER, become labeled with mannose-6-
phosphate (M6P) in the cis-Golgi complex and subsequently bind to mannose-6-
phosphate-receptor (M6PR) in the TGN (Kornfeld 1987). M6PR recruits adaptor proteins 
such as AP1 (adaptor protein-1) or GGA proteins that bind to clathrin to form clathrin-
coated vesicles. These vesicles enter the endosomes where the M6PR-bound hydrolase is 
released as a result of low pH and M6PR is recycled to TGN. The released hydrolases are 
subsequently transported to the lysosome. The direct pathway is also used by some 
lysosomal membrane proteins (LMP) but they do not require binding to M6PR. 
The indirect pathway is less understood and involves trafficking from the TGN to 
the plasma membrane by a default secretory pathway, followed by an endocytic pathway 
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to culminate in the lysosome. Many LMP use this pathway. LMP are synthesized in the 
ER, trafficked to the TGN where they are secreted to the plasma membrane by a default 
secretory pathway. On the plasma membrane, these proteins bind to AP2 (adaptor 
protein-2) and are endocytosed to be sorted to the lysosome (Janvier and Bonifacino 
2005). Unlike other hydrolases, β-glucocerebrosidase (βGC) follows the indirect pathway 
by binding to LIMP2. βGC is not labeled by M6P in cis-Golgi and it binds to LIMP2 in 
the TGN to continue on the indirect pathway via the plasma membrane.  
 
PIKfyve complex and PtdIns(3,5)P2 metabolism 
PtdIns(3,5)P2 is a phosphoinositide of low abundance that represents only about 
0.0001% of total lipids in human erythrocytes (Lemmon 2008). This is about 500 fold 
lower in comparison to PtdIns(4,5)P2 level. The presence of PtdIns(3,5)P2 was first 
detected in 1997 in yeast and mammalian cells (Dove, Cooke et al. 1997) (Whiteford, 
Brearley et al. 1997). PtdIns(3,5)P2 is synthesized from PtdIns(3)P on the endosomal 
compartments in mammalian cells by the PtdIns(3)P 5-kinase PIKfyve (also known as 
FAB1 in yeast) (Shisheva 2008).  Currently, PIKfyve is thought to be the exclusive 
enzyme for synthesis of PtdIns(3,5)P2. This notion is supported by genetic studies in 
yeast showing a complete ablation of PtdIns(3,5)P2 synthesis in Fab1-null mutants 
(Cooke, Dove et al. 1998).   
Although PIKfyve is the exclusive kinase that synthesizes PtdIns(3,5)P2, the 
kinase activity of PIKfyve is tightly regulated by other proteins that form a complex with 
PIKfyve. These proteins include the PtdIns(3,5)P2 5-phosphatase Fig4 (also known as 
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SAC3) (Gary, Sato et al. 2002, Sbrissa, Ikonomov et al. 2007) and the docking protein 
VAC14 (also known as ArPIKfyve) (Jin, Chow et al. 2008, Sbrissa, Ikonomov et al. 
2008). Although Fig4 can dephosphorylate PtdIns(3,5)P2 to PtdIns(3)P in vitro, the 
ablation of Fig4 in vivo impairs the PIKfyve-mediated synthesis of PtdIns(3,5)P2, which 
demonstrates the essential role of Fig4 in the stabilization of PIKfyve complex for its 
proper kinase activity (Chow, Zhang et al. 2007, Ikonomov, Sbrissa et al. 2009). 
Similarly, VAC14 is essential for the kinase activity of PIKfyve complex and mice 
lacking VAC14 have defective synthesis of PtdIns(3,5)P2 (Zhang, Zolov et al. 2007, Jin, 
Chow et al. 2008). 
  
PtdIns(3,5)P2 effector proteins 
PtdIns(3,5)P2 may execute its cellular functions by interacting with proteins 
containing PtdIns(3,5)P2-specific binding domain. ATG18 in yeast (also known as 
SVP1) is a multi-WD40 protein that fold as β-propeller (PROPPIN) that binds 
PtdIns(3,5)P2 with high affinity (Kd ~500nM) and specificity (Dove, Piper et al. 2004). 
In mammals, four homologues of ATG18 have been described. These include WIPI-1, 
WIPI-2, WIPI-3 and WIPI-4 (Behrends, Sowa et al. 2010). WIPI-1 binds to PtdIns(3)P 
and PtdIns(3,5)P2 (Jeffries, Dove et al. 2004, Proikas-Cezanne, Waddell et al. 2004).  
Depletion of WIPI-1 and WIPI-2 lead to increased autophagosome number, suggesting 
their essential role in autophagy suppression (Proikas-Cezanne and Robenek 2011). It is 
currently unknown whether WIPI-3 and WIPI-4 bind to phosphoinositides and carry out 
any functions in membrane trafficking.  
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Although several other proteins have been proposed to be effector proteins of 
PtdIns(3,5)P2, they bind PtdIns(3,5)P2 with significantly lower affinities compared to 
Atg18. These candidate proteins include Tup1 (WD40 domain) (Han and Emr 2011), 
Raptor (WD40 domain) (Bridges, Ma et al. 2012), SNX1 and SNX 2 (PX domain) 
(Carlton, Bujny et al. 2004, Carlton, Bujny et al. 2005), Cti 6 (PHD domain), clavesin 
(Sec14 domain) (Katoh, Ritter et al. 2009), and class II formins (PTEN domain) (van 
Gisbergen, Li et al. 2012). In addition, PtdIns(3,5)P2 also binds and activates the ion 
channels TRPML1 and RyR1 (Dong, Shen et al. 2010, Wang, Zhang et al. 2012), but the 
lipid binding domain has not been identified in these proteins.  
 
PtdIns(3,5)P2 functions 
The cellular functions of Fab1 have been initially studied in yeast mutants lacking 
Fab1 or its kinase activity.  Fab1 mutant cells exhibit enlarged vacuoles and they are 
defective in the retrograde trafficking from the vacuole to the late endosome, sorting into 
the multivesicular bodies, and acidification of the vacuole (Gary, Wurmser et al. 1998). 
Similarly, in mammalian cells , PIKfyve ablation by pharmacologic inhibition and siRNA 
knockdown decreases the intracellular synthesis of PtdIns(3,5)P2 and cells exhibit 
cytoplasmic vacuolation that express markers of early and late and/or lysosomes 
(Ikonomov, Sbrissa et al. 2001, Rutherford, Traer et al. 2006, Jefferies, Cooke et al. 2008, 
de Lartigue, Polson et al. 2009). Some studies using siRNAs-mediated knockdown of 
PIKfyve demonstrated that PIKfyve is essential in the recycling of M6PR from 
endosomes to the TGN (Rutherford, Traer et al. 2006, Zhang, Zolov et al. 2007, de 
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Lartigue, Polson et al. 2009). Similarly, fibroblasts from Vac14 knockout mice are 
deficient in the synthesis of PtdIns(3,5)P2 and they have impaired endosome-to-TGN 
trafficking (Zhang, Zolov et al. 2007). However, other studies proposed that PIKfyve is 
critical for the anterograde fusion of late endosomes with lysosomes. (Ikonomov, Sbrissa 
et al. 2003, Rusten, Rodahl et al. 2006, Jefferies, Cooke et al. 2008). Consistent with 
these findings, a study using PIKfyve inhibitor and siRNA knockdown showed that 
salmonella containing vacuoles failed to fuse with the late endosome/lysosome for its 
maturation (Kerr, Wang et al. 2010). This view is further supported by several studies 
showing that PtdIns(3,5)P2-deficient cells accumulate autophagosomes because they fail 
to mature into autophagolysosomes (Martin, Harper et al. 2013). These studies indicated 
that the PIKfyve complex and its product PtdIns(3,5)P2 are essential regulators of 
membrane homeostasis, and of vesicle trafficking and cargo transport along the 
endosomal-lysosomal pathway (Dove, Dong et al. 2009, McCartney, Zhang et al. 2014) .  
Recently, the physiological functions of PtdIns(3,5)P2 have been elucidated using 
genetically engineered mice that lack different components of the PIKfyve complex 
(Takasuga and Sasaki 2013). PIKfyve-null mice are embryonically lethal (Ikonomov, 
Sbrissa et al. 2011), but mice expressing residual PIKfyve activity are viable and develop 
defects within multiple organs, such as in the nervous, cardiopulmonary, and 
hematopoietic systems (Zolov, Bridges et al. 2012). Similarly, Fig4-null mice or Vac14-
null mice develop several defects, including neurodegeneration, hypopigmentation, and 
early lethality (Chow, Zhang et al. 2007, Zhang, Zolov et al. 2007). Notably, 
homozygous Fig4 mutations were also identified in patients who have the 
neurodegenerative diseases Charcot-Marie Tooth Syndrome 4J and Amyotrophic Lateral 
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Sclerosis (Chow, Zhang et al. 2007, Chow, Landers et al. 2009), demonstrating a role for 
PtdIns(3,5)P2 in neural development. More recently, a study using muscle-specific 
PIKfyve knockout mouse showed that PIKfyve is essential for glucose homeostasis 
(Ikonomov, Sbrissa et al. 2013). Furthermore, the loss of PIKfyve only in the intestinal 
epithelial cells results in an inflammatory bowel phenotype demonstrating that PIKfyve is 
essential for structural and functional integrity of intestinal epithelial cells (Takasuga, 
Horie et al. 2013). Together, these studies indicate that PIKfyve has an essential and 
distinct role in different types of tissues.   
 
Purpose of the thesis research 
In this thesis, my overall goal is to understand the biological role of PIKfyve in 
platelets and in megakaryocytes using mice lacking PIKfyve only in these cell types. 
Platelets are anucleated, but they store numerous biologically active substances in their 
secretory organelles, which include alpha granules, dense granules, and lysosomes. 
Platelet granules are generated in megakaryocytes from the endosomal-lysosomal system 
(Heijnen, Debili et al. 1998, Youssefian and Cramer 2000, Ambrosio, Boyle et al. 2012, 
Meng, Wang et al. 2012) by as yet, poorly understood mechanisms. Given the regulatory 
role of PIKfyve synthesis of PtdIns(3,5)P2 in endosomal-lysosomal homeostasis and 
trafficking pathway, we hypothesized that PIKfyve was essential for the biogenesis and 
function of platelet granules. We show that PIKfyve is critical for proper lysosomal 
homeostasis in platelets, but it is not necessary for the biogenesis of alpha granules or 
dense granules. Remarkably, PIKfyve-null platelets are defective in the maturation, 
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storage, and release of lysosomal enzymes. Unexpectedly, these platelet lysosomal 
defects induce aberrant inflammatory responses in macrophages that impair the 
development, body mass, fertility, and survival of mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   23	  
CHAPTER 2: MATERIALS AND METHODS 
 
Animal models.   
All animals were maintained on standard chow and tap water under specific 
pathogen-free conditions. All animal procedures were approved by the Institutional 
Animal Care and Use Committees at the University of Pennsylvania. Targeting of the 
PIKfyve gene was generated using C57BL6 mice (inGenious Targeting Laboratory). A 
bacterial artificial chromosome (BAC) derived from C57BL/6 (RPCI23) genomic DNA 
was used to construct the targeting vector. The targeting vector was designed to excise 
exons 37 and 38 of the mouse PIKfyve gene that encodes the activation loop of the kinase 
domain. The 7.55 kb long homology arm extended 5’ to exon 37, and the 1.5 kb short 
homology arm extended 3’ to exon 38. A pGK-gb2 loxP/FRT neocassette was inserted on 
the 3’ side of exon 38, and the single loxP site was inserted at the 5’ side of exon 37. The 
resulting 10.6 kb fragment was subcloned into an approximately 2.4 kb backbone vector 
(pSP72, Promega) containing an ampicillin selection cassette to generate a final targeting 
construct of 14.8 kb. C57BL/6 embryonic stem cells were electroporated with targeting 
vectors. Clones resistant to the G418 antibiotic were selected and screened by Southern 
Blot and PCR to identify recombinant ES clones. The selected clones were microinjected 
into C57BL/6 blastocysts. Resulting chimeras with black coat color were mated with 
wild-type C57BL/6 mice to generate PIKfyve F1 heterozygous offspring. F1 
heterozygous mice were crossed with a FLP transgenic mouse to excise the neomycin 
cassette that was flanked by FRT sites. The resulting F2 mosaic offspring were crossed 
with wild-type mice to generate F3 heterozygotes that were missing the neomycin 
cassette. F3 heterozygotes were crossed to generate mice carrying the PIKfyve floxed 
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allele (PIKfyvefl). PIKfyvefl/fl mice were crossed with transgenic mice expressing Cre 
recombinase under the control of the platelet factor 4 promoter (Pf4-Cre) to induce 
tissue-restricted Cre recombination in the megakaryocyte lineage. For some experiments, 
PIKfyvefl/fl mice were crossed with a B6;129S4-Gt(ROSA)26Sortm1Sor/J (Rosa26-LacZ) 
reporter strain and then with a Pf4-Cre transgenic mouse. For other experiments, 
PIKfyvefl/fl mice were crossed with B6-Cg-Pldnpa/J (pallid) mice, and their offspring were 
paired with the Pf4-Cre transgenic mice to generate PIKfyvefl/fl Pf4-Cre/pallid mice. For 
all studies, both female and male mice were used. Sex-matched littermates were used as 
controls for all studies if not indicated otherwise. 
 
PCR genotyping 
Genomic DNA isolated from mouse tail biopsies was used to genotype mice by 
PCR. The recombinant ES cells were identified with 5’- 
CCAGAGGCCACTTGTGTAGC -3’ and 5’- CAGCCAGTGCTCGCATACAAAGG -3’ 
primers. The insertion of neomycin cassette in F1 mice was identified with 5’- 
CCAGAGGCCACTTGTGTAGC -3’ and 5’- GGATGAAGTGCCTTGTTATCTGCAG -
3’ primers. The 3rd LoxP integration was identified with 5’- 
CCATTGCCTGGCTTAGAACAGAG -3’ and 5’-GAACTCTCCCGCGTAGTACAGC-
3’ primers. PCR generated products were either 310bp corresponding to the wild-type 
alleles or 370bp corresponding to the targeted allele (LoxP integrated). Pf4-Cre transgene 
was identified with 5’-CCCATACAGCACACCTTTTG-3’ and 5’-
TGCACAGTCAGCAGGTT-3’ primers. Rosa26/LacZ transgene was identified with 5’-
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AAAGTCGCTCTGAGTTGTTAT-3’, 5’-GCGAAGAGTTTGTCCTCAACC-3’ and 5’-
GGAGCGGGAGAAATGGATATG-3’.  
 
Body composition analysis 
Mice were anesthesized with sodium pentobarbital (90 mg per kg) and scanned by 
dual energy X-ray absorptiometry (DEXA) at the Mouse Metabolism Core at the 
University of Pennsylvania.  
 
Histochemistry and immunohistochemistry 
Necropsies were performed on female and male control and PIKfyvefl/fl Pf4-Cre 
mice between 3 weeks and 28 weeks of age. They included macroscopic observations, 
body and organ weight measurements, complete blood counts, serum chemistry analysis, 
and microscopic examination of the brain, thymus, lymph nodes, heart, lung, small 
intestine, large intestine, liver, spleen, pancreas, kidney, ovaries, testis, skin, muscle, fat, 
and bone marrow. Fresh postmortem tissues were fixed overnight in 10% formalin, 
paraffin-embedded and sectioned. Paraffin-sections were deparaffinized with xylene and 
ethanol, and stained with hematoxylin/eosin, PAS, and Alcian Blue. For 
immunohistochemistry, paraffin sections were deparaffinized with xylene and ethanol, 
and antigen retrieved in 0.01M citrate buffer by microwaving for 30 minutes. They were 
stained with the following primary antibodies: F4/80 (Serotec; 1:100), CD41 (BD 
Pharmingen; MWReg30; 1:50), and CD45R/B220 (BD Pharmingen; RA3-6B2; 1:500). 
Sections were counterstained with hematoxylin. For X-gal staining, frozen tissue sections 
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were fixed with 0.5% glutaraldehyde for 10 minutes, and stained overnight with the 
chromogenic substrate for β-galactosidase, X-gal (Cell Center, University of 
Pennsylvania). Sections were then counterstained with hematoxylin or hematoxylin/eosin 
as indicated.  
 
Immunoblotting 
Tissues were harvested and homogenized in RIPA buffer with a protease inhibitor 
cocktail (Roche). The protein concentrations were determined using the BCA Protein 
Assay (Pierce). Proteins were separated on SDS-PAGE gradient gels (Invitrogen) and 
then transferred onto the polyvinylidene difluoride membrane (Invitrogen). The 
membrane was blotted with the indicated primary antibodies against: PIKfyve-N-terminal 
(Sigma-Aldrich; P0054; 1:400), LAMP-1 (Developmental Studies Hybridoma Bank; 
1:1000), EEA-1 (Santa Cruz; 1:1000), Cathepsin D (Calbiochem; 1:1000), vWF (DAKO; 
1:1000), PF4 (Bethyl; 1:1000), Akt (Cell Signaling Technology; 1:1000), pAkt (Cell 
Signaling Technology; 1:1000), and b-actin (Cell Signaling Technology; 1:1000). This 
was followed by blotting with horseradish peroxidase-conjugated secondary antibodies 
and developing with enhanced chemiluminescence substrate (GE Healthcare).  
 
Megakaryocyte and platelet preparation 
Megakaryocytes were derived from the bone marrow by flushing mouse femurs 
and cultured in the presence of 1% thrombopoietin (TPO, R&D Systems) in IDMD 
supplemented with 10% FBS (Josefsson, James et al. 2011). After 4 days, cultured 
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megakaryocytes were isolated by sedimentation through a 1.5% / 3% BSA step gradient. 
To prepare washed platelets, blood was collected from the inferior vena cava of mice into 
0.1 volume of acid citrate dextrose buffer. Platelet-rich plasma was separated by 
centrifugation at 200 g for 10 minutes and incubated with 1 µM prostaglandin E1 for 10 
minutes at room temperature. Platelets were then isolated by centrifugation at 800 g for 
10 minutes and resuspended in HEPES-Tyrode buffer pH 7.4.  
 
Megakaryocyte number and ploidy analysis 
To measure the number of megakaryocytes in the bone marrow, isolated 
megakaryocytes from the bone marrow were stained with CD41 antibody conjugated 
with Alexa 488 (BD Biosciences), and cells were counted on the FACS Calibur flow 
cytometer (BD Biosciences) discriminating size to subtract out platelets. To determine 
the megakaryocyte ploidy, cells were stained with propidium iodide (Sigma) and the 
relative DNA content was measured. FlowJo software was used to analyze all flow 
cytometry data.  
 
P-selectin expression analysis 
Platelets were diluted to a density of 5 x 106 cells ml-1, stimulated with thrombin 
at indicated concentrations and then incubated with a phycoerythrin-conjugated P-
selectin antibody (BD Pharmingen). Fluorescence values were analyzed on a FACS 
Calibur flow cytometer (BD Biosciences).  
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Platelet aggregation and ATP secretion 
Platelets were diluted to a density of 2.5 x 106 cells ml-1 in HEPES-Tyrode buffer 
pH 7.4. Platelet aggregation in response to agonist stimulation was assessed by changes 
in light transmission detected by a dual-channel lumi-aggregometer (Chrono-Log) with 
stirring at 37 oC. Platelet secretion of ATP was assessed concurrently by the 
luciferin/luciferase reaction after adding chrono-lume no. 395 (Chronolog) to the 
aggregometer cuvette.  
 
Transmission electron microscopy 
Megakaryocytes grown in culture were harvested on day 6 and fixed in 
glutaraldehyde. Ultrathin sections were obtained and collected on hexagonal copper 
grids. Sections were stained with Reynold’s lead citrate and examined using transmission 
electron microscopy at the Electron Microscopy Core Facility at the University of 
Pennsylvania.  
 
Platelet depletion in vivo 
To study the effects of platelet depletion in the control mice and the PIKfyve fl/fl 
Pf4-Cre mice, female and male mice at 8-10 weeks of age were administered with GPIbα 
antibody (Emfret) at 2 µg per g twice weekly by intraperitoneal injections for a total of 6 
weeks. Blood counts were monitored weekly by collecting blood from the retro-orbital 
sinus. Body weight was monitored twice weekly. Necropsies were performed at the 
completion of 6 weeks of antibody treatment.   
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Radiation bone marrow chimeras 
Bone marrow cells were isolated from wild-type mice expressing either CD45.1 
or CD45.2 congenic markers or from PIKfyvefl/fl Pf4-Cre mice expressing CD45.2 
congenic markers. Bone marrow cells were depleted of T cells and red blood cells by 
using magnetic beads bound to antibodies against Ter119, CD3, CD4, and CD8. To study 
the phenotype rescue effect, PIKfyvefl/fl Pf4-Cre recipient mice expressing CD 45.2 
congenic markers were irradiated with 900 rads and administered by retro-orbital 
injection with 2x106 bone marrow cells from wild-type mice expressing CD 45.1 
markers. To study the phenotype transfer effect, wild-type recipient mice expressing 
CD45.1 markers were irradiated with 900 rads, and administered by retro-orbital 
injection with 1x106 bone marrow cells from wild-type mice expressing thy 1.1 marker 
and 1x106 bone marrow cells from PIKfyvefl/fl Pf4-Cre mice expressing CD 45.2 markers. 
Transplanted mice were maintained in sterile water with sulfamethoxazole/trimethoprim 
for 3 weeks.  Mice were sacrificed, and analyzed for engraftment and histology analyses 
at about 33-35 weeks after transplantation. 
 
β-hexosaminidase and cathepsin D activity assays 
The β-hexosaminidase activity was determined using a chromogenic substrate 
(Holmsen and Dangelmaier 1989). Mouse platelets or plasma were mixed with 10 mM 
substrate p-nitrophenyl-N-acetyl-β-D-glucosaminide (Sigma) in citrate-phosphate buffer 
pH 4.5. Platelet extracts were incubated for 16 hours at 37 oC, and plasma was incubated 
	   30	  
for 1 hour at 37 oC. The enzymatic reaction was stopped by the addition of 0.5 M NaOH. 
The absorbance of released p-nitrophenolate was read at 405 nm in an ELISA plate 
reader. Cathepsin D activity was determined using a fluorogenic substrate(Yasuda, 
Kageyama et al. 1999). The reaction mixture contained 10 µl of platelet lysate solution, 
10 µl of 200 µM of substrate Bz-Arg-Gly-Phe-Phe- Pro-4MeOβNA (Calbiochem), and 80 
µl of 50 mM sodium acetate buffer pH 4.0. Reaction mixtures were incubated for 30 
minutes at 37 oC. The enzymatic reaction was stopped by adding 5% TCA. The release of 
2-naphthylamine was measured in a spectrofluorometer at emission wavelength 410 nm 
and excitation wavelength 335 nm.  
 
FeCl3-induced carotid artery thrombosis assay2 
Mice were anesthetized using sodium pentobarbital (90 mg kg-1). A midline 
incision was made in the neck, and the carotid artery was exposed and dissected away 
from surrounding tissue. The artery was placed on a Doppler flow probe (Transonic 
Systems, Ithaca, NY) to monitor blood flow through the vessel. After a baseline flow 
measurement was recorded, vascular injury was initiated by placing a 1 mm2 piece of 
filter paper saturated with 7.5% FeCl3 (Sigma) on the surface of the artery for 2 minutes. 
The filter paper was then removed and the artery rinsed with saline, followed by the 
continuous recording of blood flow in the vessel for 20 minutes post-injury. The time to 
vessel occlusion was recorded.   
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 This assay was performed in collaboration with Dr. Timothy Stalker, PhD at the University of 
Pennsylvania. 
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Plasma vWF analysis 
For analysis of plasma vWF multimer distribution, mouse plasma (10 µl) was 
denatured at 60 oC for 20 minutes with 10 µl of sample buffer (70mM Tris, pH 6.8, 2.4% 
SDS, 0.67 M urea, 4 mM EDTA, 10% glycerol, 0.01% bromophenol blue). Proteins were 
fractionated on 1% agarose gel on ice and transferred to a nitrocellulose membrane. The 
membrane was blotted with vWF IgG antibody (Dako; 1:5000) to detect the vWF 
multimers. For quantification analysis of plasma vWF antigen, we performed ELISA. A 
microtiter plate coated with rabbit anti-vWF IgG (Dako; 1:2000) was incubated with 
diluted mouse plasma for 1 hour at room temperature. After washing with PBS, bound 
vWF was determined by peroxidase-conjugated rabbit anti-vWF IgG (Dako; 1:2000). A 
pre-mixed TMB (3,3’,5,5’-tetramethylbenzidine) solution was used for color 
development. The absorbance at 450 nm was determined by an ELISA plate reader.  
 
Mass spectrometry analysis3 
For the mass spectrometry analysis, platelets were isolated from three control 
mice and three PIKfyvefl/fl Pf4-Cre mice. To prepare platelet releasates, washed platelets 
(5 x 108 cells ml-1) were stimulated with 1 U ml-1 thrombin for 10 minutes at 37 oC. 
Activated platelets were centrifuged at 13,000g for 10 minutes at 4 oC and the supernates 
were isolated from the pellets. The concentrations of proteins from the platelet supernates 
were measured using the BCA protein assay (Pierce). Proteins (40 µg) were digested with 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	  The proteomics analysis and its statistical analysis were performed in collaboration with Dr. Steven 
Seeholzer, PhD and Mr. Chris McKennan at the Proteomics Core in The Children’s Hospital of 
Philadelphia.	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trypsin in solution. Tryptic digests were analyzed by LC-MS/MS on a hybrid LTQ 
Orbitrap Elite mass spectrometer (Thermofisher Scientific San Jose, CA) coupled with a 
nano LC Ultra (Eksigent).  Peptides were separated by reverse phase (RP)-HPLC on a 
nanocapillary column, 75 µm id × 15 cm Reprosil-pur  3 µM (Dr. Maisch, Germany) in a 
Nanoflex chip system (Eksigent). Mobile phase A consisted of 1% methanol 
(Fisher)/0.1% formic acid (Thermo) and mobile phase B of 1% methanol/0.1% formic 
acid/80% acetonitrile. Peptides were eluted into the mass spectrometer at 300 nl min-1 
with each RP-LC run comprising a 90 minute gradient from 10 to 25% B in 65 min, 25-
40% B in 25 min. The mass spectrometer was set to repetitively scan m/z from 300 to 
1800 (R = 240,000 for LTQ-Orbitrap Elite) followed by data-dependent MS/MS scans on 
the twenty most abundant ions, with a minimum signal of 5000, dynamic exclusion with 
a repeat count of 1, repeat duration of 30 s, exclusion size of 500 and duration of 60 s, 
isolation width of 2.0, normalized collision energy of 33, and waveform injection and 
dynamic exclusion enabled. FTMS full scan AGC target value was 1e6, while MSn AGC 
was 1e4, respectively. FTMS full scan maximum fill time was 500 ms, while ion trap 
MSn fill time was 50 ms; microscans were set at one.  FT preview mode; charge state 
screening, and monoisotopic precursor selection were all enabled with rejection of 
unassigned and 1+ charge states. 
For database search, MS/MS raw files were searched against a mouse protein 
sequence database including isoforms from the Uniprot Knowledgebase 
(taxonomy:10090 AND keyword: "Complete proteome [KW-0181]") using MaxQuant 
version 1.4.1.2 with the following set parameters: Fixed modifications, Carbamidomethyl 
(C); Decoy mode, revert; MS/MS tolerance ITMS, 0.5 Da; false discovery rate for both 
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peptides and proteins, 0.01; Minimum peptide Length, 6; Modifications included in 
protein quantification, Acetyl (Protein N-term), Oxidation (M); Peptides used for protein 
quantification, Razor and unique. The numbers of peptide spectral matches to each 
protein were used for quantitative comparison between samples.  
For quantification and statistical analysis of mass spectrometry data, we adapted a 
method proposed by Choi(Choi, Fermin et al. 2008) to use a label free model using the 
number of peptide spectral matches (PSMs) in each protein to determine the likelihood 
that the protein was differentially regulated across the control mice and the knockout 
mice. The idea is to develop a control model and a knockout model, and for each protein, 
to test whether the knockout model describes its expression data significantly better than 
the control model. To do so, we estimate a Bayes Factor !! = ! !!|!"#"! !!|!"#"  for each 
protein. We assume that the number of PSMs for protein ! in sample ! can be modeled as 
a Poisson distribution with mean λ!,!, since each element !!,! in the PSM data matrix ! is 
count data. To combat the limited number of biological replicates in each treatment 
group, we pooled information across replicates and estimate each λ!,! using a control and 
knockout hierarchical log-linear model, denoted by: 
!!: !"# λ!,!! = !!" !! + !"# !! + !! + !!                                                                           
(1) 
!!: !"# λ!,!! = !"# !! + !"# !! + !! + !! + !!!!                            
(2) 
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where !! is the length of protein !, !! is the mean number of spectral counts in 
sample !, !! = 0  !"  sample  !  is  a  control  mouse1  !"  sample  !  is  a  knockout  mouse  , !! is a model constant, !! is a 
protein’s native expression term, and !! is a protein’s knockout expression term. We give 
the model a well-defined structure by putting priors on !!~! 0, !!! , !!~! 0, !!! , and !!~! 0, !!! . To make data-driven estimates of !!! and !!!, we place hyper priors on 
these two parameters, given by !!!, !!!~InvGamma(0.1, 0.1). We let !! “float”, and 
thus set !!! = 10!. We use these parameters (denoted as a vector by !) to estimate a 
protein’s Bayes Factor: 
!! = ! !!|!! !!|! = ! ! !!,!! ! !! !! !!!! ! !!,!! ! !! !! !!! !(!!)!(!!) = !!!|!! ! ! !!,!!!!!|!! ! ! !!,!!  (assuming we 
have no prior knowledge of P(!!) and P(!!) for any protein)  = !"#!→! !! ! ! !!,!!!!!!!!"#!→! !! ! ! !!,!!!!!!!                                
(3) 
where the transition states !! → !!!! are determined using Metropolis Hastings 
and Gibbs Sampling Markov Chain Monte Carlo techniques. Specifically, at iteration ! 
with parameter vector !!! (we explain using the knockout model, since !! ⊂ !!), 
P !!! ∙   α  P ! !!!,∙ P !!! = N !!!; 0, !!! Poisson !!,! !!!,∙!!                               
(4) 
P !!! ∙   α  P !!,. !!!,∙ P !!! = N !!!; 0, !!! Poisson !!,! !!!,∙!                             
(5) 
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P !!! ∙   α  P !!,. !!!,∙ P !!! = N !!!; 0, !!! Poisson !!,! !!!,∙!                          
(6) 
P !!!! ∙   α  P !! !!!! !!!! P !!!! = InvGamma 0.1+ !! , 0.1+ !!!!!!!!                         
(7) 
P !!!! ∙   α  P !! !!!! !!!! P !!!! = InvGamma 0.1+ !! , 0.1+ !!!!!!!!                       
(8) 
where G = #proteins. 
The fold change for protein 'P' is defined as:  
Fold  change  P = !!!!!!! + !!!!!!! + !!!!!!!!!!"!!!"! + !!!"!!!"! + !!!"!!!"!   
where SC_ki is the number of spectral counts for protein 'P' in knockout replicate 'i', N_ki 
is the average number of spectral counts in knockout replicate 'i', SC_wti is the number of 
spectral counts for protein 'P' in wild type replicate 'i', and N_wti is the average number 
of spectral counts in wild type replicate 'i'. To minimize the bias in the number of spectral 
counts across conditions due to protein amount or machine performance, 6 different mass 
spectrometry runs were carried out and each run was normalized to the mean number of 
spectral counts in that run. In addition, to reduce the bias in the number of spectral counts 
caused by the length of a protein, the spectral counts were also normalized to the length 
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of protein (longer proteins tend to have more tryptic fragments and thus more spectral 
counts). 
To determine the set of proteins that significantly changed in the knockout set 
with respect to the control set, we imposed a strict cutoff and required that each protein 
have a Bayes Factor of at least 8 and a fold change of at least 2.0.  
 
Statistical analysis 
GraphPad Prism 5 was used to analyze data. All data are presented as mean ± 
S.D. Two-tailed Student’s t-tests were used for the comparison of two groups. A log rank 
test was performed for Kaplan Meier survival analysis. P-values of <0.05 (*), <0.01 (**), 
and < 0.001(***) were used to ascertain statistical significance 
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Introduction 
Phosphoinositides are minor components of membrane phospholipids, yet they 
are essential for the regulation of diverse cellular processes, including signal 
transduction, cytoskeletal control, and membrane trafficking (Di Paolo and De Camilli 
2006).  Phosphoinositide metabolism is tightly modulated by specific lipid kinases and 
phosphatases. Altering phosphoinositide turnover by dysregulating these enzymes can 
lead to a variety of human diseases (McCrea and De Camilli 2009).  
PtdIns(3,5)P2 is a phosphoinositide of low abundance that is synthesized from 
PtdIns(3)P on the endosomal compartments in mammalian cells by the lipid kinase 
PIKfyve (also known as FAB1)(Shisheva 2008). PIKfyve forms a protein complex with 
other regulatory proteins, such as the PtdIns(3,5)P2 5-phosphatase Fig4 (also known as 
SAC3) (Gary, Sato et al. 2002, Sbrissa, Ikonomov et al. 2007) and the docking protein 
Vac14 (also known as ArPIKfyve) (Jin, Chow et al. 2008, Sbrissa, Ikonomov et al. 2008). 
The PIKfyve complex and its product PtdIns(3,5)P2 are essential regulators of membrane 
homeostasis, and of vesicle trafficking and cargo transport along the endosomal-
lysosomal pathway (Dove, Dong et al. 2009, McCartney, Zhang et al. 2014) .  
Recently, physiological functions of PtdIns(3,5)P2 have been elucidated using 
genetically engineered mice that lack different components of the PIKfyve complex 
(Takasuga and Sasaki 2013). PIKfyve-null mice are embryonically lethal(Ikonomov, 
Sbrissa et al. 2011), but mice expressing residual PIKfyve activity are viable and develop 
defects within multiple organs, such as in the nervous, cardiopulmonary, and 
hematopoietic systems (Zolov, Bridges et al. 2012). Similarly, Fig4-null mice or Vac14-
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null mice develop several defects, including neurodegeneration, hypopigmentation, and 
early lethality (Chow, Zhang et al. 2007, Zhang, Zolov et al. 2007). Notably, 
homozygous Fig4 mutations were also identified in patients who have the 
neurodegenerative diseases Charcot-Marie Tooth Syndrome 4J and Amyotrophic Lateral 
Sclerosis (Chow, Zhang et al. 2007, Chow, Landers et al. 2009), demonstrating a role for 
PtdIns(3,5)P2 in neural development. Although studies showed that PtdIns(3,5)P2 
deficiency causes defects in multiple cellular pathways including those required for 
endolysosomal trafficking in yeast and mammalian cell cultures, the physiological 
consequences of PtdIns(3,5)P2 in non-neural cells, such as those of the hematopoietic 
system, are not well understood.   
Platelets are hematopoietic cells that are crucial for hemostatic plug formation in 
response to vascular injury. This process has been shown to require a series of key 
platelet activation events that are tightly regulated by several phosphoinositides (Min and 
Abrams 2013). However, the regulatory role of PtdIns(3,5)P2 in platelets remains 
unknown. Platelets are anucleated, but they store numerous biologically active substances 
in their secretory organelles, which include alpha granules, dense granules, and 
lysosomes(King and Reed 2002, Whiteheart 2011). Platelet granules are generated in 
megakaryocytes from the endosomal-lysosomal system (Heijnen, Debili et al. 1998, 
Youssefian and Cramer 2000, Ambrosio, Boyle et al. 2012, Meng, Wang et al. 2012) by 
as yet, poorly understood mechanisms.  
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In this study, we investigated whether PIKfyve plays an essential role in platelets 
and in megakaryocytes using mice lacking PIKfyve specifically in these cell types. Given 
the role of PIKfyve-mediated PtdIns(3,5)P2 production in the regulation of the 
endosomal-lysosomal pathway, we hypothesized that PIKfyve was essential for the 
biogenesis and function of platelet granules. We show that PIKfyve is critical for proper 
lysosomal homeostasis in platelets, but it is not necessary for the biogenesis of alpha 
granules or dense granules. Remarkably, PIKfyve-null platelets are defective in the 
maturation, storage, and release of lysosomal enzymes. Unexpectedly, these platelet 
lysosomal defects induce aberrant inflammatory responses in macrophages that impair 
the development, body mass, fertility, and survival of mice.  
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Loss of PIKfyve in platelets causes multiorgan defects  
To investigate the role of PIKfyve in platelets and in megakaryocytes, we 
generated mice lacking PIKfyve kinase activity specifically in these cell types. The 
PIKfyve gene was conditionally targeted with loxP sites flanking the exons corresponding 
to the kinase activation loop to generate floxed alleles of PIKfyve (PIKfyvefl, Fig. 3.1). 
Mice expressing PIKfyvefl were crossed with transgenic mice expressing the Cre 
recombinase that is controlled by the platelet-factor-4 promoter (Pf4-Cre), which restricts 
the expression of Cre recombinase exclusively within megakaryocytes and their derived 
platelets (Tiedt, Schomber et al. 2007).  
 
PIKfyvefl/fl Pf4-Cre mice developed several morphological abnormalities relative 
to their littermate PIKfyvefl/+ mice, PIKfyvefl/fl mice, and PIKfyvefl/+ Pf4-Cre mice. At 
about 3 weeks of age, PIKfyvefl/fl Pf4-Cre mice exhibited mild growth delay and body 
hair loss (Fig. 3.2a). Over time, they gradually developed coarse facial features, 
abdominal distention, a generalized increase in the bulk of their soft tissues, and body 
weight gain (Fig. 3.2b and 3.2c). Despite this weight gain, body composition analysis by 
dual-energy X-ray absorptiometry showed that PIKfyvefl/fl Pf4-Cre mice had reduced 
body fat, but increased lean body mass, as compared to their littermate controls (Fig. 
Figure 3.1. Generation of the PIKfyvefl/fl 
Pf4-Cre mouse. Schematic representation of 
genetic targeting of PIKfyve. The target 
exons 37 and 38 (red bars) were targeted 
with lox P recombination sites (yellow 
arrows) to generate PIKfyve floxed alleles 
(PIKfyvefl). Mice expressing PIKfyvefl were 
then crossed with Pf4-Cre mice to induce 
homologous recombination of the PIKfyvefl 
(PIKfyve Post-Cre). 
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3.2d). In addition, they also had decreased bone mineral density (Fig. 3.2e). As PIKfyvefl/fl 
Pf4-Cre mice aged, they remained infertile (Fig. 3.2f) and their general body functions 
deteriorated. The vast majority died before 28 weeks of age (Fig. 3.2g).  
 	  
Figure 3.2	  Platelet-specific ablation of PIKfyve causes multiorgan abnormalities in 
mice. (a) General appearance of PIKfyvefl/fl  and PIKfyvefl/fl  Pf4-Cre littermates at 3 weeks 
of age. Note the characteristic hair loss and small size in the PIKfyvefl/fl  Pf4-Cre mice. (b) 
General appearance of control and PIKfyvefl/fl Pf4-Cre littermates at 24 weeks of age. 
Note the characteristic coarse facial features, body hair loss, and severely distended body 
morphology. (c) Body weight of control mice and PIKfyvefl/fl Pf4-Cre mice. The average 
numbers of mice were 8 per time point and per group. (d) Percent of total body fat in the 
control (n=3) and PIKfyvefl/fl  Pf4-Cre (n=3) mice at 12-24 weeks of age. (e)  Bone 
mineral density of the control (n=3) and PIKfyvefl/fl  Pf4-Cre (n=3) mice at 12-24 weeks 
of age. ) (f) Number of pregnancies achieved by females (n=10) and by males (n=10) 
over 4 months of mating period. (g) Survival curves of female and male control (n= 40) 
and PIKfyvefl/fl Pf4-Cre (n= 40) mice. *P<0.05, ** P<0.01, ***P<0.001. All error bars 
indicate mean ± S.D. Student’s t-test.  
	   43	  
PIKfyvefl/fl Pf4-Cre mice accumulate vacuolated macrophages  
To elucidate the cause of multiorgan defects in PIKfyvefl/fl Pf4-Cre mice, 
histological and immunohistochemical analyses were performed in mice of 3-28 weeks of 
age. Unlike their control littermates, PIKfyvefl/fl Pf4-Cre mice exhibited massive 
organomegaly (Fig. 3.3). This phenotype reflected progressive tissue infiltration by 
engorged cells with multiple cytoplasmic vacuoles that had a “foamy” appearance (Fig. 
3.4, arrowheads). Although the vacuoles of these cells did not stain with classical dyes 
for proteins or lipids, their cytoplasm strongly stained with Alcian Blue and PAS, 
suggesting an excessive storage of acidic polysaccharides in the vacuolated cells (Fig. 
3.5a and 3.5b).  
 
 
 
Figure 3.3. PIKfyvefl/fl Pf4-Cre mice develop 
multiple organ defects. (a) Representative pictures 
of the heart, lung, liver, and intestines in the control 
PIKfyvefl/fl mice and in the PIKfyvefl/fl Pf4-Cre mice at 
24 weeks of age.  
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Figure 3.4. Inflammatory vacuolated macrophages infiltrate multiple tissues in the 
PIKfyve fl/fl Pf4-Cre mice. Representative histopathology of the lung, liver, skin and 
intestine from the control PIKfyvefl/fl mice and PIKfyvefl/fl Pf4-Cre mice at 24 weeks of 
age. Insets show images in the boxed area at higher magnification. Hematoxylin and 
eosin stain. Scale bar, 100µm, inset, 20µm. All arrowheads indicate the vacuolated cells. 
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Figure 3.5. The aberrant macrophages with cytoplasmic vacuoles store acidic 
mucosubstances. (a) Representative lung sections from the control and the PIKfyvefl/fl 
Pf4-Cre mice were stained with Alcian Blue. Scale bar, 100µm. Inset shows higher 
magnification of the boxed area. Scale bar, 20µm. (b) Representative liver sections from 
the control and the PIKfyvefl/fl Pf4-Cre mice (n=3) were stained with PAS. Scale bar, 
100µm. Inset shows higher magnification of boxed area. Scale bar, 20µm. 
 
In their livers and lungs, the vacuolated cells accumulated in a perivascular distribution 
and displaced the normal tissue, suggesting that the vacuolated cells originated from the 
blood or vasculature. By immunohistochemical analysis, the vacuolated cells stained with 
the macrophage-specific marker F4/80 (Fig. 3.6a), but not with the markers of other cell 
lineages, including GPIb (a megakaryocyte-specific marker). The F4/80-positive 
vacuolated macrophages in the livers of PIKfyvefl/fl Pf4-Cre mice were approximately 3-4 
fold larger than the F4/80-positive macrophages in the livers of the control mice 
(Fig.3.6b). In addition, tissues infiltrated with the vacuolated macrophages were often 
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associated with mononuclear cell infiltrates that stained with the lymphocyte marker 
CD45R (Fig. 3.6c), suggesting a local inflammatory response. These results demonstrate 
that the loss of PIKfyve in platelets causes the invasion of normal tissues with 
inflammatory vacuolated macrophages. 
 
 
Figure 3.6. The infiltrating vacuolated cells are inflammatory F4/80+ macrophages. 
(a) Liver structures of control mice and PIKfyvefl/fl Pf4-Cre mice were stained for 
macrophages with anti-F4/80 antibody by immunohistochemistry. Scale bar, 100µm. 
Inset shows higher magnification of the boxed area. Scale bar, 20µm. (b) Representative 
lung sections from the control and the PIKfyvefl/fl Pf4-Cre mice were stained with anti-
CD45R/B220 antibody. Scale bar, 100µm. Inset shows higher magnification of the boxed 
area. Scale bar, 20µm. All arrowheads indicate the vacuolated macrophages. 
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PIKfyve-null platelets induce macrophage pathology 
Cells from PtdIns(3,5)P2-deficient organisms have been shown to form large 
cytoplasmic vacuoles(Takasuga and Sasaki 2013, McCartney, Zhang et al. 2014). 
However, because our genetic approach was designed to only ablate PtdIns(3,5)P2 
synthesis in platelets and in megakaryocytes, we did not expect to see the robust 
cytoplasmic vacuolation in the macrophages of PIKfyvefl/fl Pf4-Cre mice. Therefore, we 
further addressed whether these unexpected macrophage abnormalities resulted from 
aberrant PIKfyve disruption in macrophages, or by non-autonomous effects of PIKfyve 
disruption in platelets. Immunoblotting analysis showed that PIKfyve protein was absent 
in platelets, but present in the liver, spleen, and lungs of PIKfyvefl/fl Pf4-Cre mice. 
PIKfyve protein was also present in all tissues of the control mice (Fig. 3.7). These 
results strongly suggest that the PIKfyve protein was ablated only in the megakaryocyte 
lineage of PIKfyvefl/fl Pf4-Cre mice.  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. PIKfyve expression is absent exclusively in the platelets of PIKfyvefl/fl 
Pf4-Cre mice. The levels of PIKfyve protein were determined in the platelets, liver, 
spleen and lung of the indicated mice by immunoblotting. Note the absence of the 
PIKfyve protein in the platelets, but its presence in the liver,spleen and lung of PIKfyvefl/fl 
Pf4-Cre mice (n=3 per group). Tissues from the wild-type mice, the PIKfyvefl/+ Pf4-Cre 
mice, and the PIKfyvefl/fl mice were used as positive controls. β-actin was used as a 
loading control.  
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Although Pf4-Cre expression has been shown to be restricted to megakaryocytes 
and platelets (Tiedt, Schomber et al. 2007, Bertozzi, Schmaier et al. 2010, Carramolino, 
Fuentes et al. 2010, Josefsson, James et al. 2011), we next re-evaluated Pf4-Cre 
expression in PIKfyvefl/fl Pf4-Cre mice by crossing them to mice expressing a Cre-
dependent LacZ reporter (Rosa26-LacZ)(Soriano 1999). Tissue staining of PIKfyvefl/fl 
Pf4-Cre/ Rosa26-Lacz mice with X-gal showed β-galactosidase expression only in 
megakaryocytes and in platelets (Fig. 3.8a, arrows), but not in the vacuolated 
macrophages or in other cells (Fig. 3.8b, arrowheads). This genetic evidence excludes the 
possibility that Pf4-Cre induced PIKfyve ablation in the macrophages of PIKfyvefl/fl Pf4-
Cre mice. Together, these results demonstrate that the macrophage infiltration and 
enlargement observed in PIKfyvefl/fl Pf4-Cre mice are indirectly induced by PIKfyve 
ablation in megakaryocytes and/or in platelets.  
 
 
 Figure 3.8. Pf4-Cre is specifically 
expressed in platelets and 
megakaryocytes. (a) X-gal staining of 
the lung tissues from PIKfyvefl/fl 
Rosa26-LacZ mice and PIKfyvefl/fl Pf4-
Cre Rosa26-LacZ mice. Scale bar, 20 
µm. The arrow indicates the platelet 
clumps in the lung vessels expressing 
LacZ (blue stain). Arrowheads indicate 
the vacuolated macrophages that did 
not stain blue. (b) Representative 
pictures of X-gal staining of the spleen 
sections from 10 week-old mice (n=5 
per group). Arrows indicate 
megakaryocytes. Note the expression 
of LacZ (blue stain) only in the 
megakaryocytes of PIKfyvefl/fl Pf4-Cre / 
Rosa-LacZ mice. Scale bar, 20µm. 
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To further address whether PIKfyve-null platelets contribute to the robust 
macrophage response leading to the multiorgan failure in PIKfyvefl/fl Pf4-Cre mice, we 
studied the effects of platelet depletion using monoclonal GP1bα antibodies(Bergmeier, 
Rackebrandt et al. 2000, Nieswandt, Bergmeier et al. 2000). Platelet depletion was 
initiated at 8-10 weeks of age. At that point, the PIKfyvefl/fl Pf4-Cre mice had already 
developed body hair loss, some weight gain, and tissue infiltration of their vacuolated 
macrophages. Control mice and PIKfyvefl/fl Pf4-Cre mice were either untreated or 
administered GP1bα antibodies twice weekly via intraperitoneal injections for 6 weeks. 
As reported previously, the injection of GP1bα antibodies efficiently induced acute 
thrombocytopenia in both sets of mice(Bergmeier, Rackebrandt et al. 2000, Nieswandt, 
Bergmeier et al. 2000). However, repetitive injections of GP1bα antibodies were less 
effective at inducing stable thrombocytopenia over time likely because of the reactive 
thrombocytopoiesis associated with complete platelet depletion with anti-platelet 
antibodies(Trowbridge and Martin 1984). Nevertheless, the PIKfyvefl/fl Pf4-Cre mice that 
were treated with GP1bα antibodies showed a significant delay in weight gain and 
attenuated hair loss as compared to the untreated PIKfyvefl/fl Pf4-Cre mice (Fig. 3.9a and 
3.9b). Together, our findings demonstrate that platelets are the primary contributors in the 
development of the inflammatory macrophage response and multiorgan defects in 
PIKfyvefl/fl Pf4-Cre mice. 
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Figure 3.9. Platelets drive the multiorgan defects in the PIKfyvefl/fl Pf4-Cre mice.  
(a) Representative general morphology of 15-weeks-old control mice and PIKfyvefl/fl Pf4-
Cre mice after 6 weeks of either no intervention (untreated) or biweekly injections of  
anti-GP1bα antibodies (+GP1bα Ab). (b) Body weight change of the control mice and 
PIKfyvefl/fl Pf4-Cre mice after 6 weeks of no intervention or treatment with anti-GP1bα 
antibodies (n=3 for each group).  *P<0.05. All error bars indicate mean ± S.D. Student’s 
t-test. 
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We also investigated whether the macrophage response in PIKfyvefl/fl Pf4-Cre 
mice could be rescued or transferred by hematopoietic stem cell (HSC) transplantation. 
Lethally irradiated wild-type mice of 8-12 weeks of age were reconstituted with a 
mixture of donor cells that were half derived from PIKfyvefl/fl Pf4-Cre HSCs and half 
derived from wild-type HSCs. Thirty-five weeks later, a necropsy showed that infiltration 
of vacuolated macrophages was readily apparent in the liver, lung, colon, and bone 
marrow of the irradiated wild-type recipient mice (Figure 3.10b and 3.10e, arrowheads). 
Conversely, lethally irradiated PIKfyvefl/fl Pf4-Cre mice of 8-12 weeks of age were 
reconstituted exclusively with wild-type donor HSCs. At about 8 weeks after 
transplantation, the characteristic hair loss and weight gain were significantly attenuated. 
A necropsy at 35 weeks after transplantation confirmed that the infiltration of the 
vacuolated macrophages in multiple tissues was completely reversed (Supplementary Fig. 
3.10c and 3.10f). Together, these results further demonstrate that the phenotype of 
PIKfyvefl/fl Pf4-Cre mice can be either rescued or transferred by hematopoietic progenitor 
cells.  
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Figure 3.10. Transplanted bone marrow cells can recapitulate or revert the tissue 
infiltration of vacuolated macrophages in PIKfyvefl/fl Pf4-Cre mice. (a-c) General 
appearance of lethally irradiated recipient mice approximately 35 weeks after the 
transplantation of hematopoietic stem cells (HSC). (a) Wild-type HSC were transplanted 
into wild-type mice. (b) Mixture of HSC half derived from wild-type HSC and half 
derived from PIKfyvefl/fl Pf4-Cre HSC were transplanted into wild-type mice (n=5 per 
group). (c) Wild-type HSC were transplanted into PIKfyvefl/fl Pf4-Cre mice. (d-f) Liver 
sections from the respective recipient mice in panels (a-c). Black arrowheads indicate the 
vacuolated macrophages. White arrows indicate vessels. Scale bar, 20µm.   
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Megakaryopoiesis and thrombopoiesis do not require PIKfyve  
We next studied the effects of PIKfyve ablation in megakaryocytes of PIKfyvefl/fl 
Pf4-Cre mice.  Fibroblasts and neurons of PtdIns(3,5)P2-deficient organisms typically 
develop large vacuoles(Takasuga and Sasaki 2013, McCartney, Zhang et al. 2014). 
Histological analysis by light microscopy of bone marrow sections showed that PIKfyve-
null megakaryocytes were morphologically indistinguishable from control 
megakaryocytes (Fig. 3.11a). However, analysis by transmission electron microscopy of 
cultured megakaryocytes derived from PIKfyvefl/fl Pf4-Cre bone marrow revealed 
multiple enlarged cytoplasmic vacuoles (Fig. 3.11b). Despite this abnormality, flow 
cytometric analysis showed no significant differences in the number of megakaryocytes 
in the bone marrow of control or PIKfyvefl/fl Pf4-Cre mice (Fig. 3.11c). Moreover, 
PIKfyve-null megakaryocytes had normal ploidy, implying that the loss of PIKfyve did 
not affect megakaryocyte maturation (Fig. 3.11d). Finally, counts of platelets and 
leukocytes as well as hemoglobin level were similar between control and PIKfyvefl/fl Pf4-
Cre mice (Fig.3.11e-g). Thus, PIKfyvefl/fl Pf4-Cre mice normally develop 
megakaryocytes in vivo and produce normal numbers of platelets, and they also normally 
develop other blood cells.  
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Figure 3.11. PIKfyve is not necessary for the development of megakaryocytes nor 
for platelet production. (a) Representative pictures of bone marrow sections from the 
control and PIKfyvefl/fl Pf4-Cre mice at 16 weeks of age. White arrows indicate 
megakaryocytes. Black arrowheads indicate the vacuolated macrophages. Scale bar 
20µm. (b) Electron micrographs of megakaryocytes grown in culture in the presence of 
thrombopoietin for 7 days. Note multiple enlarged vacuoles in the cytoplasm of 
PIKfyvefl/fl Pf4-Cre mice as compared to the control mice. Scale bar, 10 µm. (c) CD41+ 
megakaryocyte counts of control and PIKfyvefl/fl Pf4-Cre mice (n=3 for each group). (d) 
Megakaryocyte ploidy (n=3 for each group).  (e-g) Counts of platelets (e), WBC (f), and 
Hb (g) of control mice and PIKfyvefl/fl Pf4-Cre mice (n=3 for each group). All error bars 
indicate mean ± S.D. Student’s t-test. 
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PIKfyve regulates trafficking of platelet lysosomal cargoes  
We next investigated the effects of PIKfyve ablation in the morphology and 
functions of platelets in PIKfyvefl/fl Pf4-Cre mice. Transmission electron microscopy 
demonstrated that in contrast to the PIKfyve-null megakaryocytes derived from the bone 
marrow, the ultrastructure of PIKfyve-null platelets was indistinguishable from that of 
control platelets (Fig. 3.12a). To test whether the loss of PIKfyve impacted granule 
content, we assessed the abundance of representative components by immunoblotting. 
PIKfyve-null platelets expressed normal levels of the alpha granule components von 
Willebrand factor and platelet factor 4 (Fig. 3.12b-c). In contrast, PIKfyve-null platelets 
exhibited increased levels of the lysosomal protein LAMP-1 (Lysosomal-Associated 
Membrane Protein 1; Fig. 3.13a-b) and increased activity of the lysosomal enzyme β-
hexosaminidase (Fig. 3.13c). These results suggest that PIKfyve-null platelets store 
normal levels of alpha granule components, but store excessive levels of lysosomal 
components.  
 
Figure 3.12. PIKfyve is not 
required for the storage of 
platelet alpha granules.  
(a) Representative electron 
micrographs of platelets 
extracted from PIKfyvefl/fl and 
PIKfyvefl/fl Pf4-Cre mice at 3 
weeks of age. Scale bar 2µm. 
(b) Immunoblot of platelet 
lysates showing the expression 
of vWF and Pf4 in the control 
and PIKfyve-null platelets. β-
actin was used as a loading 
control. (c) Quantification of 
panel (c) (n=3). All error bars 
	   56	  
indicate mean ± S.D.    
 
To test whether PIKfyve regulates granule secretion, we stimulated platelets ex 
vivo and monitored granule release by surface expression of granule markers or release of 
mediators into the medium. Following thrombin stimulation, PIKfyve-null platelets 
translocated the α-granule protein P-selectin to their cell surface as efficiently as control 
platelets (Fig. 3.14a). Likewise, ATP secretion from dense granules was similar in control 
and PIKfyve-null platelets (Fig. 3.14b). However, the releasates from PIKfyve-null 
platelets showed increased activity of the lysosomal enzyme, β-hexosaminidase (Fig. 
3.13c).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13. PIKfyve is critical for proper storage and release of lysosomal proteins 
in platelets.  (a) Immunoblot of platelet lysates from the control mice and PIKfyvefl/fl 
Pf4-Cre mice showing the expression of EEA-1 and LAMP-1. β-actin was used as the 
loading control. (b) Quantification of protein bands shown in the panel a (n=3 for each 
group). (c) β-hexosaminidase activity in the platelet lysates of control mice (n=3) and 
PIKfyvefl/fl  Pf4-Cre mice (n=3).  
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Further analysis showed that the PIKfyve-null platelets released a normal 
percentage of their total cellular β-hexosaminidase following agonist stimulation (Fig. 
3.14c).  These data indicate that PIKfyve-null platelets release higher levels of β-
hexosaminidase than the control platelets because they contain excessive amounts of this 
lysosomal enzyme, and not because they secrete it more efficiently. Consistent with this 
finding, β-hexosaminidase activity was found to also be elevated in the plasma of 
PIKfyvefl/fl Pf4-Cre mice (Fig. 3.13c). Together, these findings demonstrate that PIKfyve-
null platelets store and release excessive levels of lysosomal cargo proteins.   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14. PIKfyve is not required for the efficient exocytosis of platelet granules. 
(a) Platelet surface translocation of P-selectin upon stimulation with thrombin at shown 
concentrations (n=3). (b) Representative graphs showing ATP secretion (green and black 
lines) and aggregation (red and blue lines) of control platelets (black and blue lines) and 
PIKfyve-null platelets (green and red lines). Platelets were stimulated with thrombin (1U 
ml-1) or collagen (10µg ml-1). (c) ß-hexosaminidase activity in the platelet releasates and 
lysates after stimulation with thrombin (1U ml-1), collagen (10µg ml-1), and ADP. White 
portions of the bar represent the enzymatic activity in the platelet releasates following 
platelet stimulation. Black portions of the bars represent the enzymatic activity in the 
residual platelet lysates after stimulation (n=3 per group).  
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To more comprehensively analyze how the loss of PIKfyve affects the contents 
secreted upon platelet activation, a quantitative proteomics analysis was performed. By 
tandem liquid chromatography- mass spectrometry (LC-MS/MS), we identified the 
proteins released from the control platelets and the PIKfyve-null platelets following 
thrombin stimulation. We then used the spectral counting of the identified peptides to 
quantitatively compare the proteins released from the control platelets and the PIKfyve-
null platelets. Using a cutoff of 2.0-fold as a significant difference between them, we 
identified 17 proteins that were increased and 38 proteins that were decreased in the 
releasates of PIKfyve-null platelets relative to wild-type platelets (Table 3.1 and 3.2). 
Among those proteins that were more abundant in the PIKfyve-null platelet releasates, 
several lysosomal enzymes stood out including cathepsin D, cathepsin B, and maltase 
(Table 3.1). Remarkably, levels of the cathepsin D were 20-fold higher in PIKfyve-null 
platelet releasates than in control releasates (Table 3.1). 
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Table 1. Upregulated proteins in the platelet releasates of PIKfyvefl/fl Pf4-Cre mice.  
The numbers of peptide spectral matches to each protein were used for quantitative 
comparison between the knockout (KO) and control (Cont) platelet samples. A Bayes 
Factor of at least 8 and a fold change of at least 2.0. were used for statistical analysis.   
 
!
Protein names Gene 
names 
Bayes 
Factor 
(KO/Cont) 
Fold Change 
(KO/Cont) 
Cathepsin D Ctsd 4757.53 20.28 
Serum amyloid A-1 protein Saa1 266.90 15.48 
Ig lambda-3 chain C region Iglc3 263.45 14.34 
Collagen alpha-1(I) chain Col1a1 116.35 12.79 
Proteasome subunit beta type-1 Psmb1 37.79 11.06 
Proteasome subunit alpha type-6 Psma6 23.52 9.82 
Fibulin-1 Fbln1 10000.00 8.87 
Phosphatidylcholine-sterol acyltransferase Lcat 8932.21 6.49 
Complement C1q subcomponent subunit A C1qa 18.07 3.46 
Properdin Cfp 749.23 3.21 
Cathepsin B Ctsb 14.55 3.21 
Apolipoprotein B Apob 10000.00 2.49 
Kininogen 2 Kng2 200.88 2.42 
Keratin, type I cytoskeletal 14 Krt14 14.80 2.33 
Maltase-glucoamilase Mgam 15.76 2.13 
Inter-alpha-trypsin inhibitor heavy chain H3 Itih3 90.05 2.01 
Complement C1s-A subcomponent C1sa 14.43 1.99 
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Table 2. Downregulated proteins in the platelet releasates of PIKfyvefl/fl Pf4-Cre 
mice.	  	  
The numbers of peptide spectral matches to each protein were used for quantitative 
comparison between the knockout (KO) and control (Cont) platelet samples. A Bayes 
Factor of at least 8 and a fold change of at least 2.0. were used for statistical analysis.   
 
!
Protein names Gene 
names 
Bayes 
Factor 
(KO/Cont) 
Fold 
Change 
(KO/Cont) Tropomyosin alpha-4 chain Tpm4 10000.00 -24.53 
Myosin light polypeptide 6 Myl6 82.14 -12.77 
Major urinary protein 20 Mup20 83.75 -12.57 
Fermitin family homolog 3 Fermt3 248.02 -12.55 
Zyxin Zyx 254.52 -11.85 
Filamin-A Flna 10000.00 -11.07 
Coagulation factor XIII A chain F13a1 28.51 -10.91 
Apolipoprotein C-III Apoc3 139.36 -10.85 
Beta-parvin Parvb 28.66 -10.68 
Protein disulfide-isomerase A3 Pdia3 80.52 -10.15 
Glyceraldehyde-3-phosphate dehydrogenase Gapdh 1515.81 -9.97 
Arachidonate 12-lipoxygenase, 12S-type Alox12 17.36 -9.42 
von Willebrand factor Vwf 10000.00 -7.77 
Latent-transforming growth factor beta-binding 
protein 1 
Ltbp1 1574.75 -6.72 
Myosin regulatory light polypeptide 9 Myl9 404.59 -6.62 
Interleukin-1 receptor accessory protein Il1rap 1016.67 -6.18 
Bridging integrator 2 Bin2 250.57 -6.09 
Alpha-actinin-1 Actn1 10000.00 -5.84 
14-3-3 protein eta Ywhah 14.60 -5.34 
Multimerin-1 Mmrn1 10000.00 -5.09 
Vinculin Vcl 10000.00 -4.69 
L-lactate dehydrogenase A chain Ldha 224.16 -4.63 
Talin-1 Tln1 10000.00 -4.53 
Galectin-3-binding protein Lgals3bp 738.58 -4.36 
Tubulin beta-4B chain;Tubulin beta-4A chain Tubb4b 760.98 -4.14 
WD repeat-containing protein 1 Wdr1 799.62 -4.13 
Transforming growth factor beta-1 Tgfb1 37.64 -3.38 
Tubulin alpha-1B chain Tuba1b 596.11 -3.33 
Heat shock cognate 71 kDa protein Hspa8 33.49 -3.03 
Myosin-9 Myh9 10000.00 -2.94 
Tubulin beta-1 chain Tubb1 133.34 -2.73 
Glia-derived nexin Serpine2 153.71 -2.68 
78 kDa glucose-regulated protein Hspa5 30.58 -2.68 
Coagulation factor V F5 10000.00 -2.61 
Metalloproteinase inhibitor 3 Timp3 10.45 -2.59 
Afamin Afm 1394.27 -2.58 
Cofilin-1 Cfl1 8.85 -2.54 
14-3-3 protein zeta/delta Ywhaz 10.93 -2.30 
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Further analysis of the sequence coverage and MS spectra of the tryptic peptides 
for cathepsin D demonstrated that the releasates of PIKfyve-null platelets contained 
predominantly the procathepsin D - the immature and inactive proenzyme form of 
cathepsin D – but undetectable levels of mature cathepsin D (Fig. 3.15a-c). To further 
validate these findings, we analyzed the expression of cathepsin D in platelet lysates by 
immunoblotting. Consistent with the proteomics data, both cathepsin D and procathepsin 
D were undedetectable in the lysates of wild-type platelets, and procathepsin D was 
highly elevated in PIKfyve-null platelets (Fig. 3.15d). These results suggest that cathepsin 
D expression is upregulated in PIKfyve-null platelets, but that the intracellular maturation 
of procathepsin D is defective in PIKfyve-null platelets. Consequently, cathepsin D 
activity was negligible in both the lysates and releasates of both wild-type and the 
PIKfyve-null platelets (Fig. 3.15e). Together, these data demonstrate that PIKfyve 
ablation in platelets results in a defective lysosomal pathway reflected by abnormal 
storage, maturation, and release of lysosomal enzymes.  
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Figure 3.15. PIKfyve-null platelets release increased levels of procathepsin D. (a) 
Amino acid sequence of murine cathepsin D. The signal peptide sequence is crossed out 
and the propeptide sequence is underlined. The trypic peptides of cathepsin D are 
highlighted in yellow. (b) The assigned MS2 spectra of the tryptic peptides contained in 
the Cathepsin D propeptide are shown. (c) The peptide TTEPVSELLK spans the 
propeptide cleavage site. Note that the predicted N-terminal tryptic peptide of the active 
form of cathepsin D (EPVSELLK) was not observed in MS1 nor identified in MS2 with 
semi-tryptic enzyme specificity for the database search. (d) Immunoblot of platelet 
lysates from control mice and PIKfyvefl/fl Pf4-Cre mice showing the expression of 
Procathepsin D. β-actin was used as the loading control (e) Cathepsin D activity of 
platelets from control and PIKfyve-null platelets in the absence or presence of protease 
inhibitor (n=3 per group).  
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Loss of PIKfyve in platelets accelerates arterial thrombosis 
Platelets have long been known to contain primary lysosomes and release their 
lysosomal enzymes in response to stimuli(Bentfeld-Barker and Bainton 1982, Rendu, 
Marche et al. 1987), but the physiologic role of platelet lysosome secretion has not been 
clearly delineated. Thus, we tested whether the lysosomal abnormalities observed in 
PIKfyve-null platelets correlated with any functional abnormalities. Washed platelets 
from control or PIKfyvefl/fl Pf4-cre mice formed aggregates to a similar degree in response 
to different agonists (Fig. 3.14b), suggesting that activation of the dominant platelet 
integrin, aIIbb3, is intact in the PIKfyve-null platelets. In addition, Akt phosphorylation 
was normally induced upon stimulation (Fig. 3.16b), suggesting that the intracellular 
signaling pathway in PIKfyve-null platelets is also preserved. To determine the effect of 
PIKfyve ablation in platelets during thrombosis in vivo, the carotid arteries of mice were 
analyzed for occlusive thrombus formation in response to a chemical injury with ferric 
chloride. At 12-16 weeks of age, PIKfyvefl/fl Pf4-Cre mice formed occluding thrombi 
significantly faster than their control littermates (3.8 ± 1.6 minutes vs. 6.1 ± 1.2 minutes, 
Fig. 3.16a). Since PIKfyve-null platelets showed normal aggregation ex vivo, we 
speculated that the excessive secretion of the platelet lysosomal contents from PIKfyve-
null platelets could contribute to endothelial damage and systemic inflammation leading 
to accelerated thrombus formation. Consistent with this possibility, plasma levels of 
vWF, a marker of endothelial damage and systemic inflammation(Lip and Blann 1997), 
were significantly elevated in the plasma of PIKfyvefl/fl Pf4-Cre mice when measured by 
immunoblotting (Fig. 3.16c) or ELISA (Fig. 3.16d). Together, these results suggest that 
excessive lysosomal secretion from PIKfyve-null platelets is associated with endothelial 
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damage and systemic inflammation, perhaps underlying excessive thrombosis in 
PIKfyvefl/fl Pf4-Cre mice. 
 
 
 
Figure 3.16. Loss of PIKfyve in platelets accelerates arterial thrombosis.  (a) Time to 
occlusion of carotid arteries upon vascular injury with 7.5% of FeCl3 in the control mice 
(n=9) and the PIKfyvefl/fl Pf4-Cre mice (n=8). (b) Immunoblot of platelet lysates from 
control platelets and PIKfyvefl/fl Pf4-Cre platelets showing the Akt phosphorylation in 
resting condition or stimulated with 1U/mL of thrombin for 10 minutes. (c) SDS agarose 
electrophoresis showing the multimer pattern of plasma vWF from the control mice (n=3) 
and the PIKfyvefl/fl Pf4-Cre (n=3) mice. (d) Plasma levels of vWF from the control mice 
(n=3) and the PIKfyvefl/fl  Pf4-Cre (n=3) mice were quantified by ELISA. *P<0.05. All 
error bars indicate mean ± S.D. Student’s t-test. 
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Impaired release of platelet lysosomes reverts the pathology 
If the pathological macrophage inflammatory response in PIKfyvefl/fl Pf4-Cre mice 
reflects the excessive stimulus-induced secretion of lysosomal enzymes, we hypothesized 
that attenuating the release of platelet lysosomes would comparably attenuate the 
inflammatory responses. To test this hypothesis, PIKfyvefl/fl Pf4-Cre mice were crossed 
with pallid mice, a model of Hermansky-Pudlak Syndrome type 9 (Cullinane, Curry et al. 
2011). Pallid mice lack an essential subunit of BLOC-1, a complex required for the 
biogenesis of lysosome-related organelles such as pigment cell melanosomes and platelet 
dense granules (Marks, Heijnen et al. 2013, Wei and Li 2013). Importantly, stimulus-
dependent secretion of lysosomal contents is impaired (but not ablated) in platelets from 
pallid mice (Novak, Hui et al. 1984). In contrast to PIKfyvefl/fl Pf4-Cre mice that 
developed persistent dorsal alopecia and weight gain, PIKfyvefl/fl Pf4-Cre/pallid mice 
maintained hair growth until death and exhibited attenuated weight gain (Fig. 3.17a and 
3.17b; note that because the pallid mutation also impairs melanosome biogenesis, pallid 
mice exhibit hypopigmented fur). As expected, platelet and plasma levels of b-
hexosaminidase were lower in PIKfyvefl/fl Pf4-Cre/pallid mice than in PIKfyvefl/fl Pf4-Cre 
mice (Fig. 3.17c and 3.17d). Together, these data suggest that the release of platelet 
lysosomes contributes to the pathogenesis of multiorgan defects in PIKfyvefl/fl Pf4-Cre 
mice.  
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Figure 3.17. Impaired secretion of platelet lysosomes attenuates the phenotypes of 
PIKfyvefl/fl  Pf4-Cre mice. (a) General appearance of PIKfyvefl/fl Pf4-Cre mice and 
PIKfyvefl/fl Pf4-Cre/pallid mice on C57BL/6 background at 17 weeks of age. In the 
presence of the pallid mutation, the hair loss and weight gain are attenuated in the 
PIKfyvefl/fl  Pf4-Cre/pallid mice. Note that the pallid mice have an underlying defect in 
melanosome biogenesis causing hypopigmented fur. (b) Body weight of the PIKfyvefl/fl 
Pf4-Cre mice, and the sex-matched and age-matched PIKfyvefl/fl Pf4-Cre/pallid mice. The 
average numbers of mice were 5 per time point and per group. The dashed line indicates 
the mean ratio of body weight of the control mice. (c,d) Analysis of β-hexosaminidase 
activity in the platelet lysate (c) and plasma (d) of the PIKfyvefl/fl Pf4-Cre mice (n=3) and 
the PIKfyvefl/fl Pf4-Cre/pallid (n=3) mice. *P<0.05, ** P<0.01. All error bars indicate 
mean ± S.D. Student’s t-test. 
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CHAPTER 4: SUMMARY, DISCUSSION AND FUTURE DIRECTIONS 
 
4.1) Summary 
In this work, we show that PIKfyve kinase activity is critical in limiting the 
pathological inflammatory and thrombotic functions of platelet lysosomes. Our data 
indicate that PIKfyve kinase activity in platelets is essential for the normal maturation of 
cathepsin D and for the proper storage and release of lysosomal enzymes. Unexpectedly, 
dysregulated lysosomal homeostasis and enhanced lysosomal release from PIKfyve-null 
platelets drive an aberrant inflammatory response in macrophages. This leads to chronic 
inflammation and arterial thrombosis that affect the development, body mass, fertility, 
and survival of mice.  
 
4.2) Discussion and future studies 
PIKfyve regulation of platelet secretome 
Our proteomic analysis by mass spectrometry identified 55 proteins that were 
differentially expressed in the releasates of PIKfyve-null platelets in comparison to the 
releasates of control platelets. These include 17 up-regulated proteins and 38 down-
regulated proteins. Among all these proteins, 41 proteins (75% of total) have been 
previously reported as platelet-released proteins using a mass spectrometry-based 
approach (Coppinger, Cagney et al. 2004, Coppinger, O'Connor et al. 2007, Hernandez-
Ruiz, Valverde et al. 2007, Maynard, Heijnen et al. 2007, Piersma, Broxterman et al. 
2009). 
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Among those 17 proteins that were up-regulated in the releasates of PIKfyve-null 
platelets, three proteins are lysosomal enzymes (cathepsin D, cathepsin B and maltase-
glucoamilase) and two proteins belong to the proteasome subunits (proteasome subunit 
alpha type 6 and proteasome subunit beta type 1).  Because both the lysosome and the 
proteasome are the two main organelles for intracellular degradation, it is tempting to 
speculate that in the absence of PIKfyve, a defective lysosomal degradative function may 
feedback on the proteasome and activate the proteasomal degradative pathway.  
Six of the up-regulated proteins in the releasates of PIKfyve-null platelets are 
acute phase reactants including proteins of the complement activation system 
(complement c1s subcomponent, complement c1q subcomponent and complement factor 
properdin), cholesterol metabolism (apolipoprotein B, phosphatidylcholine-sterol 
acyltransferase) and serum amyloid a-1 protein. Although all these proteins have been 
previously identified in the platelet releasates, they also belong to the plasma proteins. It 
is possible that these acute phase proteins may just reflect an active inflammatory 
response by PIKfyve-null platelets. However, we cannot exclude the possibility that some 
of these proteins represent plasma contaminants in the platelet releasate samples. Other 
proteins that were found also up-regulated in the platelet releasates of PIKfyve-null 
platelets include two extracellular matrix proteins normally absent in platelets (collagen 
and fibulin1), immunoglobulin light chains, kininogen 2, keratin and inter-alpha-trypsin 
inhibitor. However, the significance of the differential expression of these proteins in 
PIKfyve-null platelet releasates is currently unknown.      
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Cytoskeletal proteins have been consistently reported in the platelet releasates in 
the previous studies using a proteomic approach (Coppinger, Cagney et al. 2004, 
Hernandez-Ruiz, Valverde et al. 2007, Maynard, Heijnen et al. 2007), which suggest that 
they are authentic components of platelet releasates. Among those 38 down-regulated 
proteins in the releasates of PIKfyve-null platelets, 14 proteins are cytoskeletal proteins 
(tropomyosin, myosin light polypeptide 6, zyxin, filamin A, myosin regulatory light 
polypeptide 9, alpha-actinin 1, vinculin, talin 1, tubulin beta 4B chain, WD repeat-
containing protein 1, tubulin alpha 1B chain, myosin 9, tubulin beta 1 chain and cofilin1). 
Interestingly, our immunoblotting analysis of platelet lysates for actin, tubulin and 
vinculin demonstrated no differences between the WT and PIKfyve-null platelets, which 
suggests that the total amount of cytoskeletal proteins is likely intact in PIKfyve-null 
platelets. The significance of a potential decrease of cytoskeletal proteins in the releasates 
of PIKfyve-null platelets remains to be explored.   
Other proteins that are expressed lower in the PIKfyve-null platelet releasates 
include 13 proteins that have been previously detected in the releasates of platelet alpha 
granules or dense granules (Hernandez-Ruiz, Valverde et al. 2007, Maynard, Heijnen et 
al. 2007). These proteins include factor XIII A chain, beta parvin, protein disulfide-
isomerase A3, vWF, latent-transforming growth factor beta binding protein, 14-3-3 
protein eta, multimerin-1, transforming growth factor beta 1, heat shock cognate 71kDa 
protein, glia-derived nexin, 78kDa glucose-regulated protein, coagulation factor V, 
metalloproteinase inhibitor 3 and 14-3-3 protein zeta/delta. To validate these findings, we 
performed immunoblotting analysis of vWF and PF4 in the lysates from WT and 
PIKfyve-null platelets. Interestingly, similar to the cytoskeletal proteins, the expression of 
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vWF and PF4 was similar in the lysates from the WT and PIKfyve-null platelets. In 
addition, the secretion of P-selectin and ADP were also normal in thrombin-stimulated 
PIKfyve-null platelets, which suggests that the efficiency of exocytosis of alpha granules 
and dense granules are intact in PIKfyve-null platelets. Therefore, although our proteomic 
analysis provided a comprehensive list of potential candidate proteins that could be 
differentially expressed in the PIKfyve-null platelet releasates, it is essential that these 
findings need to be validated by a separate experimental approach before we draw any 
final conclusion.  
Label-free mass spectrometry-based quantitative proteomics is a powerful 
technology for the analysis of protein abundance between samples. However, there still 
exist several limitations. 1) The use of spectral counts as a method of quantification only 
provides relative abundance of proteins in samples. In our study, the spectral counts were 
used to compare the abundance of a specific protein in the WT vs. PIKfyve-null platelet 
samples, but not for the analysis of relative abundance across different proteins. 2) The 
presence of highly abundant proteins may reduce the detection sensitivity of lower 
abundant proteins or peptides. This limitation may explain why the β-hexosaminidase 
level was found to be higher in the PIKfyve-null platelets using a chromogenic activity 
assay but not by mass spectrometry analysis. 3) Because mass spectrometry analysis is 
based on protein digests or peptides, information on the intact protein cannot be directly 
provided.   
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The role of PIKfyve in the maturation of lysosomal enzymes.   
We show that the precursor lysosomal protease, procathepsin D, is excessively 
stored and released in PIKfyve-null platelets, which suggests that PIKfyve is essential in 
the maturation of procathepsin D to active cathepsin D. In normal physiological 
conditions, cathepsin D is synthesized as a pre-pro-enzyme in the endoplasmic reticulum. 
After removal of signal peptide, pre-pro-cathepsin D yields procathepsin D, which is 
modified by N-linked glycosylation and transported to Golgi. In Golgi, procathepsin D is 
further modified by the addition of mannose-6-phosphate residues (M6P), which bind to 
the mannose-6-phosphate receptors (M6PR) in the TGN for its delivery to endosomes. In 
the acidic endolysosomal compartments, procathepsin D is further processed by 
proteolytic cleavage to active cathepsin D (Kornfeld 1987). The M6PR must then recycle 
to the TGN for another round of transport. Therefore, procathepsin D maturation depends 
on the proper trafficking of procathepsin D from the TGN to endosomes for its 
proteolytic activation in acidic compartments. Hence, the defective maturation and 
accumulation of procathepsin D in PIKfyve-null platelets suggest that PIKfyve is critical 
for procathepsin D trafficking from the TGN to endosomes. This conclusion is consistent 
with a published study showing that PtdIns(3,5)P2 deficiency leads to the defective 
retrograde trafficking of M6PR from endosomes to the TGN (Rutherford, Traer et al. 
2006), which would ultimately exhaust the M6PR from the TGN and result in a defective 
maturation and default secretion of procathepsin D. Similarly, the fibroblasts of Vac14-
null mice develop defective steady-state localization of M6PR, and they also accumulate 
the immature forms of cathepsin D (Zhang, Zolov et al. 2007). Together, these studies 
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suggest that the PIKfyve synthesis of PtdIns(3,5)P2 regulates the trafficking from the 
TGN to the lysosome, essential for the maturation of procathepsin D.  
However, the proteolytic maturation of procathepsin D also needs low pH in the 
lysosome. Consequently, a defective lysosomal acidification may also impair the 
proteolytic maturation of procathepsin D. In yeasts, PIKfyve is required for acidification 
of the lysosome-like vacuole (McCartney, Zhang et al. 2014). However, chemical 
inhibition and siRNA knockdown of PIKfyve in mammalian cells do not impair the low 
pH of endolysosomal comparments (Kim, Dayam et al. 2014). These studies suggest that 
PIKfyve might have a different role in the regulation of lysosomal pH in yeasts and 
mammalian cells. In future studies, it would be important to verify the lysosomal 
acidification as well as cellular functions that depend on the proper lysosomal 
acidification in PIKfyve-null mammalian cells.  
 
The role of PIKfyve in the expression of lysosomal proteins  
We also show that PIKfyve-null platelets have increased expression of lysosomal 
proteins, which include lysosomal membrane proteins such as LAMP-1 as well as 
lysosomal enzymes such as β-hexosaminidase and procathepsin D. These findings 
suggest that PtdIns(3,5)P2 deficiency might additionally feedback on lysosomal protein 
biosynthesis.  
The gene network of lysosomal biogenesis and functions is tightly regulated by 
the master regulator transcription factor EB (TFEB) (Sardiello, Palmieri et al. 2009, 
Settembre, Fraldi et al. 2013). In basal conditions, TFEB is phosphorylated and localized 
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in the cytoplasm. However, in response to lysosomal dysfunction or starvation, TFEB is 
dephosphorylated and rapidly translocated into the nucleus. Phosphorylation of TFEB has 
been shown to be regulated by different kinases including mTORC1, ERK2 and PKCβ 
(Settembre, Fraldi et al. 2013). Interestingly, PIKfyve synthesis of PtdIns(3,5)P2 has been 
shown to be critical for the recruitment of mTORC1 to the plasma membrane and its 
activation in adipocytes (Bridges, Ma et al. 2012). In yeast, PtdIns(3,5)P2 recruits 
TORC1 to the lysosome-like vacuole and induces multiple TORC1-dependent pathways 
(Jin, Mao et al. 2014). However, whether PIKfyve synthesis of PtdIns(3,5)P2 and its 
activation of mTORC1 is necessary for the phosphorylation of TFEB to keep it inactive 
in the cytosol remains unknown. In our preliminary study, we found that PIKfyve-
deficient cells have increased dephosphorylated forms of TFEB in their cell lysates (data 
not shown), which suggests that PIKfyve is required for the phosphorylation of TFEB. In 
future studies, one could test the hypothesis that PIKfyve deficiency impairs the 
activation of mTORC1 pathway and therefore the phosphorylation of TFEB, which 
results in the nuclear translocation of TFEB and activation of the lysosomal gene 
network. This hypothesis could be tested by comparing in the control and PIKfyve-null 
cells : 1) the activation of mTORC1 pathway by immunoblotting analysis, 2) the cellular 
localization of TFEB (cytosolic vs. nuclear) by immunofluorescence microscopy 
analysis, and 3) the expression of lysosomal genes by microarray analysis or quantitative 
RT-PCR. The impaired activation of mTORC1, nuclear translocation of TFEB, and 
increased transcripts of lysosomal genes in PIKfyve-null cells could explain the increased 
expression of lysosomal proteins in these cells.  
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The role of PIKfyve in the regulation of lysosomal functions 
Although our study on the maturation of lysosomal enzymes was limited to 
procathepsin D in PIKfyve-null platelets, a defective protein trafficking from the TGN to 
endosomes could potentially impair the processing and functions of many lysosomal 
proteins and interfere with normal lysosomal functions. Most mammalian cells have 
lysosomes and their functions are mainly intracellular. For example, within the cell, 
lysosomes are critical for the degradation and recycling of extracellular materials, 
autophagy, nutrient sensing, and control of energy metabolism (Settembre, Fraldi et al. 
2013). However, lysosomes can be exocytosed by professional secretory cells in 
physiological processes and the released lysosomal contents play essential roles at the 
extracellular space. These professional secretory cells include cytotoxic T lymphocytes 
that release granzyme and perforin for cytotoxicity, osteoclasts that release proteases for 
bone resorption, melanocytes that release and transfer melanin to keratinocytes for 
pigmentation, and platelets. However, the physiological role of the platelet secretion of 
lysosomes is poorly understood.  
Megakaryocytes and platelets possess lysosomes that contain different hydrolases 
including proteases and glycosidases, which are released upon platelet activation 
(Bentfeld and Bainton 1975, Bentfeld-Barker and Bainton 1982) (Ciferri, Emiliani et al. 
2000). It has been speculated that the release of platelet lysosomal enzymes may be 
required for the remodeling of extracellular matrix during wound healing (Rendu and 
Brohard-Bohn 2001). In addition, the pathological release of lysosomal enzymes may 
also cause the local injury of the vascular wall leading to atherosclerosis and the focal 
thickening of arteries (Muir and Bowyer 1984). Thus, proper regulation of the platelet 
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lysosomal secretion would be essential to maintain a normal response to wound healing, 
and also to avoid the inflammatory and thrombotic defects that could result from the 
excessive platelet lysosomal secretion. Consistent with this concept, this study shows that 
the excessive storage and secretion of lysosomal enzymes from platelets lacking PIKfyve 
result in the accelerated arterial thrombosis and inflammation observed in PIKfyvefl/fl Pf4-
Cre mice. Thus, our studies further support that an aberrant release of platelet lysosomal 
contents could be pathogenic and that the lysosomal homeostasis in platelets play a 
crucial role in limiting the proinflammatory and prothrombotic functions of platelets.  
 
PtdIns(3,5)P2 deficiency is reminiscent of lysosomal storage disorders 
Similar to PIKfyve-null platelets, excessive release of the lysosomal enzymes are 
also seen in the lysosomal storage disorders, Mucolipidosis II and Mucolipidosis III 
(Platt, Boland et al. 2012). In these diseases, an inability to generate the M6P recognition 
signal on the lysosomal enzymes impairs their delivery from the TGN to the lysosome via 
the M6PR pathway resulting in the excessive release of lysosomal enzymes 
extracellularly (Vogel, Payne et al. 2009).  
Like PIKfyve deficiency, the deficiency of the inositol phosphatase and PIKfyve 
chaperone protein called Fig4 results in the reduced intracellular PtdIns(3,5)P2 
concentrations. Notably, Fig4-deficient mice develop enlarged endolysosomal vacuoles 
and excessive accumulation of lysosomal proteins, reminiscent of lysosomal storage 
diseases (Zhang, Chow et al. 2008).  
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Likewise, mice lacking another PIKfyve-binding partner called Vac14 have 
decreased synthesis of PtdIns(3,5)P2 and develop excessive vacuolation of late 
endosomal and lysosomal compartments(Zhang, Zolov et al. 2007). Together with our 
findings, these studies further support that the depletion of PtdIns(3,5)P2 by impairing 
any components of the PIKfyve complex could lead to the features that are reminiscent of 
those found in lysosomal storage disorders.  
 
PIKfyve deficiency induces secondary pathologies in other cells  
It is notable that lysosomal storage diseases are frequently associated with 
inappropriate immune responses that result in chronic inflammation. For example, tissue 
infiltration of reactive macrophages can lead to visceral organomegaly in both Gaucher 
and Niemann-Pick diseases (Boven, van Meurs et al. 2004, Vitner, Platt et al. 2010). 
Likewise, microglial activation is frequently associated with the neuropathology in 
Mucopolysaccaridoses (Parkinson-Lawrence, Shandala et al. 2010).  
Similar to these findings, we unexpectedly observed that the ablation of PIKfyve 
in platelets causes inflammatory responses that are associated with robust macrophage 
defects, which lead to multiorgan failure in mice. Using several lines of evidence, we 
demonstrated that this macrophage phenotype is non-cell-autonomous, showing that 
PIKfyve-null platelets can induce aberrant responses in normal macrophages. We further 
demonstrate that impairing the lysosomal secretion from platelets significantly attenuates 
the macrophage pathology leading to multiorgan abnormalities in PIKfyvefl/fl Pf4-Cre 
mice, which suggests that platelet release of lysosomes contribute to the macrophage 
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pathology. However, the exact mechanism by which the lysosomal contents of PIKfyve-
null platelets induce the macrophage pathology remains unknown. Further studies are 
required to identify what components of platelet lysosomes contribute to the macrophage 
pathology. A strong candidate protein is the procathepsin D, which is the lysosomal 
protein with the highest relative abundance in the releasates of PIKfyve-null platelets in 
comparison to control platelets. One could test whether the releasates from PIKfyve-null 
platelets can directly contribute to the vacuolation and/or proliferation of macrophages by 
culturing WT macrophages in the presence of either the control or PIKfyve-null platelet 
releasates, and observing the morphological changes and cell proliferation by live cell 
imaging and biochemical assays. Similarly, WT macrophages could be treated either in 
the presence or in the absence of a recombinant procathepsin D, and examined for 
changes in their cell morphology or proliferation.  
Once a specific PIKfyve-null platelet lysosomal proteins causing the macrophage 
pathology is identified, further studies will be necessary to determine how this protein 
induces cytoplasmic vacuolation and cell proliferation in macrophages. Similar to 
PIKfyve-null platelets, several cancer cells overexpress and hypersecrete procathepsin D. 
In some conditions, procathepsin D has a paracrine function in the tumor environment by 
increasing fibroblast outgrowth and tumor metastasis. One proposed model is that 
procathepsin D could function as a signaling molecule that activates MAPK signaling 
pathway and regulate cellular apoptosis and proliferation in cancer cells (Vetvicka, 
Vashishta et al. 2010). Thus, it would be intriguing to investigate whether the addition of 
PIKfyve-null platelet releasates could activate MAPK signaling pathway in  WT 
macrophages. It has been also shown that the secreted procathepsin D by cancer cells can 
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be endocytosed by other cells in the tumor microenvironment and change the degradative 
functions of the lysosomes in the recipient cells. In future studies, it would be interesting 
to study whether the procathepsin D released by PIKfyve-null platelets could be 
endocytosed by WT macrophages and impair the lysosomal degradative functions leading 
to lysosomal vacuolation in macrophages.  
Interestingly, this inflammatory response has not been described in mice lacking 
Fig4 or Vac14. This could be explained because these mice do not survive long enough to 
fully develop the robust tissue accumulation of macrophages seen in PIKfyvefl/fl Pf4-Cre 
mice. However, a similar non-cell-autonomous phenomenon has also been observed in 
Fig4-null mice, which have a neurodegenerative disorder (Chow, Zhang et al. 2007). The 
genetic restoration of Fig4 exclusively in the neuronal cells of Fig4-null mice not only 
reverts the dysfunctions of neuronal cells, but it also reverts the dysfunctions of the 
adjacent oligodendrocytes including hypomyelination and maturation defects (Winters, 
Ferguson et al. 2011). Together with our findings, these studies indicate that the depletion 
of PtdIns(3,5)P2 in a single cell type may have indirect implications in other cell types. 
Furthermore, they also show that our findings are consistent with the broad secondary 
defects shown in lysosomal storage disorders.  
 
4.3) Conclusion 
Our study demonstrates the novel finding that PIKfyve kinase activity is a critical 
regulator of the lysosomal pathway in mouse platelets. This work also provides evidence 
that in addition to the effects mediated by the release of platelets alpha and dense 
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granules, secretion of platelet lysosomes may be a previously unrecognized initiator of 
vascular damage and inflammatory responses. These findings could have important 
implications and applications in the diagnosis and in the design of novel targets for 
clinical disorders mediated by platelets. 
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